WO2016112398A1 - Patient remote and associated methods of use with a nerve stimulation system - Google Patents
Patient remote and associated methods of use with a nerve stimulation system Download PDFInfo
- Publication number
- WO2016112398A1 WO2016112398A1 PCT/US2016/012918 US2016012918W WO2016112398A1 WO 2016112398 A1 WO2016112398 A1 WO 2016112398A1 US 2016012918 W US2016012918 W US 2016012918W WO 2016112398 A1 WO2016112398 A1 WO 2016112398A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- stimulation
- pulse generator
- level
- patient remote
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/372—Arrangements in connection with the implantation of stimulators
- A61N1/37211—Means for communicating with stimulators
- A61N1/37235—Aspects of the external programmer
- A61N1/37247—User interfaces, e.g. input or presentation means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36057—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for stimulating afferent nerves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36128—Control systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/372—Arrangements in connection with the implantation of stimulators
- A61N1/37211—Means for communicating with stimulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/372—Arrangements in connection with the implantation of stimulators
- A61N1/37211—Means for communicating with stimulators
- A61N1/37235—Aspects of the external programmer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/372—Arrangements in connection with the implantation of stimulators
- A61N1/37211—Means for communicating with stimulators
- A61N1/37235—Aspects of the external programmer
- A61N1/37241—Aspects of the external programmer providing test stimulations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36128—Control systems
- A61N1/36132—Control systems using patient feedback
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36128—Control systems
- A61N1/36142—Control systems for improving safety
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36128—Control systems
- A61N1/36146—Control systems specified by the stimulation parameters
Definitions
- the present invention relates to neurostimulation treatment systems and associated devices, as well as methods of treatment, implantation and configuration of such treatment systems.
- the clinically effective range of the neurostimulation system can be determined by a physician or the clinician programmer when setting the parameters of the neurostimulation system.
- the patient remote can also allow a patient to turn off the neurostimulation system, which may be desirable for the patient when performing activities that may inadvertently interfere with, or be inadvertently interfered by, the neurostimulation system and the nerves stimulated by the neurostimulation system.
- each stimulation level increase or stimulation level decrease of the pulse generator comprises more than five percent (5%), optionally at least ten percent (10%) of a nominal stimulation level or a current stimulation level.
- the patient remote can further include a stimulation-level display disposed on the exterior surface of the portable housing.
- the patient remote may be configured to wirelessly communicate with the pulse generator and the stimulation-level display may be configured to indicate a current stimulation level of the pulse generator when the activation switch of the patient remote is switched from the asleep mode to the awake mode.
- the stimulation-level display can include a plurality of light emitting diodes, where a number of illuminated light emitting diodes indicates the current stimulation level of the pulse generator.
- the stimulation-level display can include at least seven light emitting diodes of at least two, three or four sizes, where a baseline stimulation level can be indicated by illumination of (for example) the first three or four light emitting diodes.
- the therapy -remaining display light emitting diode can illuminate with a non-flashing green color to indicate at least four (4) days of therapy remaining, can illuminate with a non-flashing amber color to indicate two to four (2-4) days of therapy remaining, and can illuminate with a flashing amber color to indicate less than two (2) days of therapy remaining.
- the patient remote can further include an automatic fault condition indicator disposed on the exterior surface of the portable housing that is configured to provide an alert if the pulse generator is in a fault condition.
- the patient remote can further include a haptic indicator coupled to the portable housing that is configured to vibrate when a command from the patient remote has been executed by the pulse generator.
- the nerve-stimulating pulse generator can include an external or implantable pulse generator, and the implantable lead comprises at least one electrode configured for insertion into a foramen of a sacrum near a sacral nerve.
- a patient remote is configured to wirelessly control a nerve- stimulating pulse generator coupled to an implantable lead, the patient remote having: a portable housing configured to be operable in a single hand of an operator and circuitry at least partially disposed within the housing; an activation switch disposed within a recessed area of the portable housing so as to allow reconfiguration or transition between an awake mode and an asleep mode; a stimulation-increase switch disposed on an exterior surface of the portable housing, configured to wirelessly increase a stimulation level of the pulse generator; and a stimulation-decrease switch disposed on the exterior surface of the portable housing, configured to wirelessly decrease a stimulation level of the pulse generator; where when the recessed activation switch of the patient remote is in the asleep mode, the stimulation-increase switch and the stimulation-decrease switch are inactivated, and where when the recessed activation switch of the patient remote is in the awake mode, the patient remote is configured to wirelessly communicate with the pulse generator.
- the therapy-remaining display light emitting diode can illuminate with a non-flashing green color to indicate at least four (4) days of therapy remaining, can illuminate with a non-flashing amber color to indicate two to four (2-4) days of therapy remaining, and can illuminate with a flashing amber color to indicate less than two (2) days of therapy remaining.
- the patient remote can further have an automatic fault condition indicator disposed on the exterior surface of the portable housing configured to provide an alert if the pulse generator is in a fault condition.
- the patient remote can further have a haptic indicator coupled to the portable housing configured to vibrate when a command from the patient remote has been executed by the pulse generator.
- the present disclosure is directed to a method for controlling a nerve-stimulating pulse generator coupled to an implantable lead within a patient with a patient remote, the method including: wirelessly communicating with the pulse generator after an activation switch of the patient remote reconfigures or transitions the patient remote from an asleep mode to an awake mode; displaying a current stimulation setting of the pulse generator on a stimulation-level display of the patient remote; and wirelessly increasing a stimulation level or turning on stimulation of the pulse generator when a stimulation-increase switch of the patient remote is actuated for a first period of time or turning on and restoring stimulation of the pulse generator to a previously stored stimulation level when the stimulation-increase switch of the patient remote is actuated for a second period of time.
- the method can include displaying a status of therapy remaining in the pulse generator on the patient remote, where the therapy remaining status is based on at least a charge or voltage remaining in a battery of the pulse generator and stimulation use parameters by the patient.
- the present disclosure is directed to a method for controlling a nerve-stimulating pulse generator coupled to an implantable lead within a patient with a patient remote, the method at least including actuating an activation switch to switch a patient remote between an awake mode and an asleep mode, where when the patient remote in the awake mode: actuating a stimulation-increase switch for a first period of time to turn on or incrementally increase the stimulation level of the pulse generator or actuating the stimulation-increase switch for a second period of time to turning on and restoring stimulation of the pulse generator to a previously stored stimulation level; and actuating a stimulation-decrease switch for the first period of time to turn off or incrementally decrease the stimulation level of the pulse generator or actuating the stimulation-decrease switch for the second period of time
- the present disclosure is directed to an implantable nerve stimulation system having an implantable neurostimulator and a portable patient remote configured to wirelessly control the implantable neurostimulator
- the portable patient remote can include: an external housing having an oblong or rectangular shape; a stimulation- increase switch disposed on an exterior surface of the portable housing configured to wirelessly increase a stimulation level of the implantable neurostimulator; a stimulation- decrease switch disposed on the exterior surface of the portable housing configured to wirelessly decrease a stimulation level of the implantable neurostimulator; and a recessed activation switch disposed on the external housing and having an awake mode and an asleep mode, where when the recessed activation switch of the patient remote is in the asleep mode, the stimulation-increase switch and the stimulation-decrease switch are inactivated, and where when the recessed activation switch of the patient remote is in the awake mode, the patient remote is configured to wirelessly communicate with the implantable neurostimulator and actuation of the stimulation-increase switch for a first period of time increases the stimulation level
- the present disclosure is directed to a system for treating a patient with a disorder associated with a nerve, where the system includes a nerve-stimulating pulse generator having wireless communication circuitry and a plurality of stimulation levels; an implantable lead configured to be coupled with the pulse generator and implanted in the patient in operative communication with the nerve; and a patient remote.
- a nerve-stimulating pulse generator having wireless communication circuitry and a plurality of stimulation levels
- an implantable lead configured to be coupled with the pulse generator and implanted in the patient in operative communication with the nerve
- FIG. 1 schematically illustrates a nerve stimulation system, which includes a clinician programmer and a patient remote used in positioning and/or programming of both a trial neurostimulation system and a permanently implanted neurostimulation system, in accordance with aspects of the invention.
- FIGS. 2A-2C show diagrams of the nerve structures along the spine, the lower back and sacrum region, which may be stimulated in accordance with aspects of the invention.
- FIG. 4 shows an example of a neurostimulation system having an implantable stimulation lead, an implantable pulse generator, and an extemal charging device, in accordance with aspects of the invention.
- FIG. 5A-5C show detail views of an implantable pulse generator and associated components for use in a neurostimulation system, in accordance with aspects of the invention.
- FIGS. 7-8 show signal characteristics of a neurostimulation program, in accordance with aspects of the invention.
- FIG. 9 is a schematic illustration of a patient remote, in accordance with aspects of the invention.
- FIGS. 9-1 to 9-7 are schematic illustrations of a patient remote showing a progression of stimulation levels, in accordance with aspects of the invention.
- FIGS. 9-8 and 9-9 are schematic illustrations of a patient remote with a therapy- remaining display showing levels of therapy remaining for a neurostimulation system, in accordance with aspects of the invention.
- FIG. 9-10 is a schematic illustration of a patient remote with an illuminated fault condition indicator, in accordance with aspects of the invention.
- FIG. 10 is a functional block diagram of components of a patient remote, in accordance with aspects of the invention.
- Neurostimulation or neuromodulation as may be used interchangeably hereunder treatment systems, such as any of those described herein, can be used to treat a variety of ailments and associated symptoms, such as acute pain disorders, movement disorders, affective disorders, as well as bladder related dysfunction.
- pain disorders that may be treated by neurostimulation include failed back surgery syndrome, reflex sympathetic dystrophy or complex regional pain syndrome, causalgia, arachnoiditis, and peripheral neuropathy.
- Movement orders include muscle paralysis, tremor, dystonia and Parkinson's disease.
- Affective disorders include depressions, obsessive-compulsive disorder, cluster headache, Tourette syndrome and certain types of chronic pain.
- the methods and systems described herein are particularly suited for treatment of urinary and fecal dysfunctions. These conditions have been historically under- recognized and significantly underserved by the medical community.
- OAB is one of the most common urinary dysfunctions. It is a complex condition characterized by the presence of bothersome urinary symptoms, including urgency, frequency, nocturia and urge incontinence. It is estimated that about 33 million Americans suffer from OAB. Of the adult population, about 30% of all men and 40% of all women live with OAB symptoms.
- OAB symptoms can have a significant negative impact on the psychosocial functioning and the quality of life of patients. People with OAB often restrict activities and/or develop coping strategies.
- OAB imposes a significant financial burden on individuals, their families, and healthcare organizations.
- the prevalence of co-morbid conditions is also significantly higher for patients with OAB than in the general population.
- Co-morbidities may include falls and fractures, urinary tract infections, skin infections, vulvovaginitis, cardiovascular, and central nervous system pathologies. Chronic constipation, fecal incontinence, and overlapping chronic constipation occur more frequently in patients with OAB.
- BoNT-A Botulinum Toxin
- PTNS Percutaneous Tibial Nerve Stimulation
- SNM Sacral Nerve Stimulation
- PTNS therapy consists of weekly, 30- minute sessions over a period of 12 weeks, each session using electrical stimulation that is delivered from a hand-held stimulator to the sacral plexus via the tibial nerve.
- ongoing sessions typically every 3-4 weeks, are needed to maintain symptom reduction.
- Efficacy of PTNS has been demonstrated in a few randomized-controlled studies, however, long-term safety and effectiveness of PTNS is relatively unknown at this time.
- the trial phase is a test stimulation period where the patient is allowed to evaluate whether the therapy is effective.
- the first is an office-based procedure termed the
- PNE Percutaneous Nerve Evaluation
- a foramen needle is typically used first to identify the optimal stimulation location, usually at the S3 level, and to evaluate the integrity of the sacral nerves. Motor and sensory responses are used to verify correct needle placement, as described in Table 1 below.
- a temporary stimulation lead (a unipolar electrode) is then placed near the sacral nerve under local anesthesia. This procedure can be performed in an office setting without fluoroscopy.
- the temporary lead is then connected to an external pulse generator (EPG) taped onto the skin of the patient during the trial phase.
- EPG external pulse generator
- the stimulation level can be adjusted to provide an optimal comfort level for the particular patient. The patient will monitor his or her voiding for 3 to 7 days to see if there is any symptom improvement.
- the advantage of the PNE is that it is an incision free procedure that can be performed in the physician's office using local anesthesia.
- the disadvantage is that the temporary lead is not securely anchored in place and has the propensity to migrate away from the nerve with physical activity and thereby cause failure of the therapy. If a patient fails this trial test, the physician may still recommend the staged trial as described below. If the PNE trial is positive, the temporary trial lead is removed and a permanent quadri-polar tined lead is implanted along with an IPG under general anesthesia.
- Other neuromodulation applications may have any number of electrodes and more than one lead as the therapy may require.
- a staged trial involves the implantation of the permanent quadri-polar tined stimulation lead into the patient from the start. It also requires the use of a foramen needle to identify the nerve and optimal stimulation location.
- the lead is implanted near the S3 sacral nerve and is connected to an EPG via a lead extension. This procedure is performed under fluoroscopic guidance in an operating room and under local or general anesthesia.
- the EPG is adjusted to provide an optimal comfort level for the patient and the patient monitors his or her voiding for up to two weeks. If the patient obtains meaningful symptom improvement, he or she is considered a suitable candidate for permanent implantation of the IPG under general anesthesia, typically in the upper buttock area, as shown in FIGS. 1 and 3 A.
- Table 1 Motor and Sensory Responses of SNM at Different Sacral Nerve Roots
- pudendal afferents may turn on voiding reflexes by suppressing exaggerated guarding reflexes, thus relieving symptoms of patients with urinary retention so normal voiding can be facilitated.
- SNM stimulates pudendal afferent somatic fibers that inhibit colonic propulsive activity and activates the internal anal sphincter, which in turn improves the symptoms of fecal incontinence patients.
- the present invention relates to a system adapted to deliver neurostimulation to targeted nerve tissues in a manner that disrupt, inhibit, or prevent neural activity in the targeted nerve tissues so as to provide therapeutic effect in treatment of OAB or bladder related dysfunction.
- neurostimulation to delivery therapy at sub-threshold levels.
- Neurostimulation relies on consistently delivering therapeutic stimulation from a pulse generator, via one or more neurostimulation electrodes, to particular nerves or targeted regions.
- the neurostimulation electrodes are provided on a distal end of an implantable lead that can be advanced through a tunnel formed in patient tissue.
- Implantable neurostimulation systems provide patients with great freedom and mobility, but it may be easier to adjust the neurostimulation electrodes of such systems before they are surgically implanted. It is desirable for the physician to confirm that the patient has desired motor and/or sensory responses before implanting an IPG.
- demonstrating appropriate motor responses may be highly beneficial for accurate and objective lead placement while the sensory response may not be required or not available (e.g., patient is under general anesthesia).
- Placement and calibration of the neurostimulation electrodes and implantable leads sufficiently close to specific nerves can be beneficial for the efficacy of treatment.
- aspects and embodiments of the present disclosure are directed to aiding and refining the accuracy and precision of neurostimulation electrode placement. Further, aspects and embodiments of the present disclosure are directed to aiding and refining protocols for setting therapeutic treatment signal parameters for a stimulation program implemented through implanted neurostimulation electrodes.
- patients Prior to implantation of the permanent device, patients may undergo an initial testing phase to estimate potential response to treatment. As discussed above, PNE may be done under local anesthesia, using a test needle to identify the appropriate sacral nerve(s) according to a subj ective sensory response by the patient.
- Other testing procedures can involve a two-stage surgical procedure, where a quadri-polar tined lead is implanted for a testing phase to determine if patients show a sufficient reduction in symptom frequency, and if appropriate, proceeding to the permanent surgical implantation of a neuromodulation device. For testing phases and permanent implantation, determining the location of lead placement can be dependent on subjective qualitative analysis by either or both of a patient or a physician.
- EMG electrosenor
- the signals can be analyzed to detect activation level or recruitment order.
- EMG can be performed through the skin surface of a patient, intramuscularly or through electrodes disposed within a patient near target muscles, or using a combination of external and internal structures.
- EMG can be used to determine if the related muscle is activated, (i.e. whether the muscle fully contracts, partially contracts, or does not contract) in response to the stimulus. Accordingly, the degree of activation of a muscle can indicate whether an implantable lead or
- neurostimulation electrode is located in the desired or correct location on a patient. Further, the degree of activation of a muscle can indicate whether a neurostimulation electrode is providing a stimulus of sufficient strength, amplitude, frequency, or duration to affect a treatment regimen on a patient.
- EMG provides an objective and quantitative means by which to standardize placement of implantable leads and neurostimulation electrodes, reducing the subjective assessment of patient sensory responses.
- positional titration procedures may optionally be based in part on a paresthesia or pain-based subjective response from a patient.
- EMG triggers a measureable and discrete muscular reaction.
- the measureable muscular reaction can be a partial or a complete muscular contraction, including a response below the triggering of an observable motor response, such as those shown in Table 1, depending on the stimulation of the target muscle.
- the efficacy and outcome of the permanently implanted system is more consistent with the results of the trial period, which moreover leads to improved patient outcomes.
- FIG. 1 schematically illustrates an exemplary nerve stimulation system, which includes both a trial neurostimulation system 200 and a permanently implanted
- the clinician programmer 60 is used by a physician to adjust the settings of the EPG and/or IPG while the lead is implanted within the patient.
- the clinician programmer can be a tablet computer used by the clinician to program the IPG, or to control the EPG during the trial period.
- the clinician programmer can also include capability to record stimulation-induced electromyograms to facilitate lead placement and programming.
- the patient remote 70 can allow the patient to turn the stimulation on or off, or to vary stimulation from the IPG while implanted, or from the EPG during the trial phase.
- the clinician programmer 60 has a control unit which can include a microprocessor and specialized computer-code instructions for implementing methods and systems for use by a physician in deploying the treatment system and setting up treatment parameters.
- the clinician programmer generally includes a user interface which can be a graphical user interface, an EMG module, electrical contacts such as an EMG input that can couple to an EMG output stimulation cable, an EMG stimulation signal generator, and a stimulation power source.
- the stimulation cable can further be configured to couple to any or all of an access device (e.g., a foramen needle), a treatment lead of the system, or the like.
- the EMG input may be configured to be coupled with one or more sensory patch electrode(s) for attachment to the skin of the patient adjacent a muscle (e.g., a muscle enervated by a target nerve).
- Other connectors of the clinician programmer may be configured for coupling with an electrical ground or ground patch, an electrical pulse generator (e.g., an EPG or an IPG), or the like.
- the clinician programmer can include a module with hardware and computer-code to execute EMG analysis, where the module can be a component of the control unit microprocessor, a pre-processing unit coupled to or in-line with the stimulation and/or sensory cables, or the like.
- the clinician programmer is configured to operate in combination with an EPG when placing leads in a patient body.
- the clinician programmer can be electronically coupled to the EPG during test simulation through a specialized cable set.
- the test simulation cable set can connect the clinician programmer device to the EPG and allow the clinician programmer to configure, modify, or otherwise program the electrodes on the leads connected to the EPG.
- the electrical pulses generated by the EPG and IPG are delivered to one or more targeted nerves via one or more neurostimulation electrodes at or near a distal end of each of one or more leads.
- the leads can have a variety of shapes, can be a variety of sizes, and can be made from a variety of materials, which size, shape, and materials can be tailored to the specific treatment application.
- the lead is of a suitable size and length to extend from the IPG and through one of the foramen of the sacrum to a targeted sacral nerve
- the leads may be, for example, implanted in a peripheral portion of the patient's body, such as in the arms or legs, and can be configured to deliver electrical pulses to the peripheral nerve such as may be used to relieve chronic pain. It is appreciated that the leads and/or the stimulation programs may vary according to the nerves being targeted.
- FIGS. 2A-2C show diagrams of various nerve structures of a patient, which may be used in neurostimulation treatments, in accordance with aspects of the invention.
- FIG. 2A shows the different sections of the spinal cord and the corresponding nerves within each section.
- the spinal cord is a long, thin bundle of nerves and support cells that extend from the brainstem along the cervical cord, through the thoracic cord and to the space between the first and second lumbar vertebra in the lumbar cord.
- the nerve fibers split into multiple branches that innervate various muscles and organs transmitting impulses of sensation and control between the brain and the organs and muscles.
- certain nerves may include branches that innervate certain organs, such as the bladder, and branches that innervate certain muscles of the leg and foot
- stimulation of the nerve at or near the nerve root near the spinal cord can stimulate the nerve branch that innervate the targeted organ, which may also result in muscle responses associated with the stimulation of the other nerve branch.
- certain muscle responses such as those in Table 1, either visually, through the use of EMG as described herein or both
- the physician can determine whether the targeted nerve is being stimulated. While stimulation at a certain threshold may trigger the noted muscle responses, stimulation at a sub-threshold level may still provide stimulation to the nerve associated with the targeted organ without causing the corresponding muscle response, and in some embodiments, without causing any paresthesia. This is advantageous as it allows for treatment of the condition by neurostimulation without otherwise causing patient discomfort, pain or undesired muscle responses.
- FIG. 2B shows the nerves associated with the lower back section, in the lower lumbar cord region where the nerve bundles exit the spinal cord and travel through the sacral foramens of the sacrum.
- the neurostimulation lead is advanced through the foramen until the neurostimulation electrodes are positioned at the anterior sacral nerve root, while the anchoring portion of the lead proximal of the stimulation electrodes are generally disposed dorsal of the sacral foramen through which the lead passes, so as to anchor the lead in position.
- FIG. 2C shows detail views of the nerves of the lumbosacral trunk and the sacral plexus, in particular, the S1-S5 nerves of the lower sacrum.
- the S3 sacral nerve is of particular interest for treatment of bladder related dysfunction, and in particular OAB.
- FIG. 3A schematically illustrates an example of a fully implanted neurostimulation system 100 adapted for sacral nerve stimulation.
- Neurostimulation system 100 includes an IPG implanted in a lower back region and connected to a neurostimulation lead extending through the S3 foramen for stimulation of the S3 sacral nerve.
- the lead is anchored by a tined anchor portion 30 that maintains a position of a set of neurostimulation electrodes 40 along the targeted nerve, which in this example, is the anterior sacral nerve root S3 which enervates the bladder so as to provide therapy for various bladder related dysfunctions.
- Implantable neurostimulation systems can be used to either stimulate a target peripheral nerve or the posterior epidural space of the spine.
- Properties of the electrical pulses can be controlled via a controller of the implanted pulse generator. In some embodiments, these properties can include, for example, the frequency, strength, pattern, duration, or other aspects of the electrical pulses. These properties can include, for example, a voltage, a current, or the like.
- This control of the electrical pulses can include the creation of one or more electrical pulse programs, plans, or patterns, and in some embodiments, this can include the selection of one or more pre-existing electrical pulse programs, plans, or patterns.
- the implantable neurostimulation system 100 includes a controller in the IPG having one or more pulse programs, plans, or patterns that may be pre-programmed or created as discussed above. In some embodiments, these same properties associated with the IPG may be used in an EPG of a partly implanted trial system used before implantation of the permanent neurostimulation system 100.
- FIG. 3B shows a schematic illustration of a trial neurostimulation system 200 utilizing an EPG patch 81 adhered to the skin of a patient, particularly to the abdomen of a patient, the EPG 80 being encased within the patch.
- the lead is hardwired to the EPG, while in another the lead is removably coupled to the EPG through a port or aperture in the top surface of the flexible patch 81. Excess lead can be secured by an additional adherent patch.
- the EPG patch is disposable such that the lead can be disconnected and used in a permanently implanted system without removing the distal end of the lead from the target location. Alternatively, the entire system can be disposable and replaced with a permanent lead and IPG.
- an EMG obtained via the clinician programmer using one or more sensor patches can be used to ensure that the leads are placed at a location proximate to the target nerve or muscle, as discussed previously.
- the trial neurostimulation system utilizes an EPG 80 within an EPG patch 81 that is adhered to the skin of a patient and is coupled to the implanted neurostimulation lead 20 through a lead extension 22, which is coupled with the lead 20 through a connector 21.
- This extension and connector structure allows the lead to be extended so that the EPG patch can be placed on the abdomen and allows use of a lead having a length suitable for permanent implantation should the trial prove successful.
- This approach may utilize two percutaneous incisions, the connector provided in the first incision and the lead extensions extending through the second percutaneous incision, there being a short tunneling distance (e.g., about 10 cm) there between. This technique may also minimize movement of an implanted lead during conversion of the trial system to a permanently implanted system.
- the EPG unit is wirelessly controlled by a patient remote and/or the clinician programmer in a similar or identical manner as the IPG of a permanently implanted system.
- the physician or patient may alter treatment provided by the EPG through use of such portable remotes or programmers and the treatments delivered are recorded on a memory of the programmer for use in determining a treatment suitable for use in a permanently implanted system.
- the clinician programmer can be used in lead placement, programming and/or stimulation control in each of the trial and permanent nerve stimulation systems.
- each nerve stimulation system allows the patient to control stimulation or monitor battery status with the patient remote. This configuration is advantageous as it allows for an almost seamless transition between the trial system and the permanent system.
- the systems will operate in the same manner and be controlled in the same manner, such that the patient's subjective experience in using the trial system more closely matches what would be experienced in using the permanently implanted system.
- this configuration reduces any uncertainties the patient may have as to how the system will operate and be controlled such that the patient will be more likely to convert a trial system to a permanent system.
- the EPG 80 is encased within a flexible laminated patch 81, which include an aperture or port through which the EPG 80 is connected to the lead extension 22.
- the patch may further an "on/off ' button 83 with a molded tactile detail to allow the patient to turn the EPG on and/or off through the outside surface of the adherent patch 81.
- the underside of the patch 81 is covered with a skin-compatible adhesive 82 for continuous adhesion to a patient for the duration of the trial period.
- a breathable strip having skin-compatible adhesive 82 would allow the EPG 80 to remain attached to the patient continuously during the trial, which may last over a week, typically two weeks to four weeks, or even longer.
- FIG. 4 illustrates an example neurostimulation system 100 that is fully implantable and adapted for sacral nerve stimulation treatment.
- the implantable system 100 includes an IPG 10 that is coupled to a neurostimulation lead 20 that includes a group of neurostimulation electrodes 40 at a distal end of the lead.
- the lead includes a lead anchor portion 30 with a series of tines extending radially outward so as to anchor the lead and maintain a position of the neurostimulation lead 20 after implantation.
- the lead 20 may further include one or more radiopaque markers 25 to assist in locating and positioning the lead using visualization techniques such as fluoroscopy.
- the IPG provides monopolar or bipolar electrical pulses that are delivered to the targeted nerves through one or more neurostimulation electrodes, typically four electrodes.
- the lead In sacral nerve stimulation, the lead is typically implanted through the S3 foramen as described herein.
- the IPG is rechargeable wirelessly through conductive coupling by use of a charging device 50 (CD), which is a portable device powered by a rechargeable battery to allow patient mobility while charging.
- the CD is used for transcutaneous charging of the IPG through RF induction.
- the CD can either be either patched to the patient's skin using an adhesive or can be held in place using a belt 53 or by an adhesive patch 52, such as shown in the schematic of FIG. 6.
- the CD may be charged by plugging the CD directly into an outlet or by placing the CD in a charging dock or station 51 that connects to an AC wall outlet or other power source.
- the system may further include a patient remote 70 and clinician programmer 60, each configured to wirelessly communicate with the implanted IPG, or with the EPG during a trial, as shown in the schematic of the nerve stimulation system in FIG. 6.
- the clinician programmer 60 may be a tablet computer used by the clinician to program the IPG and the EPG.
- the device also has the capability to record stimulation-induced electromyograms (EMGs) to facilitate lead placement, programming, and/or re-programming.
- EMGs stimulation-induced electromyograms
- the patient remote may be a battery-operated, portable device that utilizes radio-frequency (RF) signals to communicate with the EPG and IPG and allows the patient to adjust the stimulation levels, check the status of the IPG battery level, and/or to turn the stimulation on or off.
- RF radio-frequency
- FIG. 5A-5C show detail views of the IPG and its internal components.
- the pulse generator can generate one or more non-ablative electrical pulses that are delivered to a nerve to control pain or cause some other desired effect, for example to inhibit, prevent, or disrupt neural activity for the treatment of OAB or bladder related dysfunction .
- the pulses having a pulse amplitude in a range between 0 mA to 1,000 mA, 0 mA to 100 mA, 0 mA to 50 mA, 0 mA to 25 mA, and/or any other or intermediate range of amplitudes may be used.
- One or more of the pulse generators can include a processor and/or memory adapted to provide instructions to and receive information from the other components of the implantable neurostimulation system.
- the processor can include a microprocessor, such as a commercially available microprocessor from Intel® or Advanced Micro Devices, Inc.®, or the like.
- An IPG may include an energy storage feature, such as one or more capacitors, and typically includes a wireless charging unit.
- One or more properties of the electrical pulses can be controlled via a controller of the IPG or EPG.
- these properties can include, for example, the frequency, strength, pattern, duration, or other aspects of the timing and magnitude of the electrical pulses.
- These properties can further include, for example, a voltage, a current, or the like.
- This control of the electrical pulses can include the creation of one or more electrical pulse programs, plans, or patterns, and in some embodiments, this can include the selection of one or more pre-existing electrical pulse programs, plans, or patterns.
- the IPG 10 includes a controller having one or more pulse programs, plans, or patterns that may be created and/or pre-programmed.
- the IPG can be programmed to vary stimulation parameters including pulse amplitude in a range from 0 mA to 10 mA, pulse width in a range from 50 to 500 ⁇ 8, pulse frequency in a range from 5 Hz to 250Hz, stimulation modes (e.g., continuous or cycling), and electrode configuration (e.g., anode, cathode, or off), to achieve the optimal therapeutic outcome specific to the patient.
- stimulation parameters including pulse amplitude in a range from 0 mA to 10 mA, pulse width in a range from 50 to 500 ⁇ 8, pulse frequency in a range from 5 Hz to 250Hz, stimulation modes (e.g., continuous or cycling), and electrode configuration (e.g., anode, cathode, or off), to achieve the optimal therapeutic outcome specific to the patient.
- stimulation modes e.g., continuous or cycling
- electrode configuration e.g., anode, cathode, or off
- a Balseal® connector block is electrically connected to four platinum / iridium alloy feed-through pins which are brazed to an alumina ceramic insulator plate along with a titanium alloy flange.
- This feed-through assembly is laser seam welded to a titanium-ceramic brazed case to form a complete hermetic housing for the electronics.
- the number of header electrical contacts is a function of the number of electrodes and leads used for any particular system configuration.
- the ceramic and titanium brazed case is utilized on one end of the IPG where the ferrite coil and PCB antenna assemblies are positioned.
- a reliable hermetic seal is provided via a ceramic-to-metal brazing technique.
- the zirconia ceramic may comprise a 3Y-TZP (3 mol percent Yttria- stabilized tetragonal Zirconia Poly crystals) ceramic, which has a high flexural strength and impact resistance and has been commercially utilized in a number of implantable medical technologies. It will be appreciated, however, that other ceramics or other suitable materials may be used for construction of the IPG.
- utilization of ceramic material provides an efficient, radio-frequency- transparent window for wireless communication with the external patient remote and clinician's programmer as the communication antenna is housed inside the hermetic ceramic case.
- This ceramic window has further facilitated miniaturization of the implant while maintaining an efficient, radio-frequency -transparent window for long term and reliable wireless communication between the IPG and external controllers, such as the patient remote and clinician programmer.
- the IPG's wireless communication is generally stable over the lifetime of the device, unlike prior art products where the communication antenna is placed in the header outside the hermetic case. The communication reliability of such prior art devices tends to degrade due to the change in dielectric constant of the header material in the human body over time.
- the ferrite core is part of the charging coil assembly 15, shown in FIG. 5B, which is positioned inside the ceramic case 14.
- the ferrite core concentrates the magnetic field flux through the ceramic case as opposed to the metallic case portion 17.
- This configuration maximizes coupling efficiency, which reduces the required magnetic field and in turn reduces device heating during charging.
- the magnetic field flux is oriented in a direction perpendicular to the smallest metallic cross section area, heating during charging is minimized.
- This configuration also allows the IPG to be effectively charged at depth of 3 cm with the CD, when positioned on a skin surface of the patient near the IPG and reduces re-charging time.
- FIG. 6 shows a setup for a test stimulation and EMG sensing using a clinician programmer 60.
- the clinician programmer 60 is a tablet computer with software that runs on a standard operating system.
- the clinician programmer 60 includes a communication module, a stimulation module and an EMG sensing module.
- the communication module communicates with the IPG and/or EPG in the medical implant communication service frequency band for programming the IPG and/or EPG.
- sensory response is a subjective evaluation and may not always be available, such as when the patient is under general anesthesia.
- EMG is a tool which records electrical activity of skeletal muscles. This sensing feature provides an objective criterion for the clinician to determine if the sacral nerve stimulation results in adequate motor response rather than relying solely on subjective sensory criteria.
- EMG can be used not only to verify optimal lead position during lead placement, but also to provide a standardized and more accurate approach to determine electrode thresholds, which in turn provides quantitative information supporting electrode selection for programming. Using EMG to verify activation of motor responses can further improve the lead placement performance of less experienced operators and allow such physicians to perform lead placement with confidence and greater accuracy.
- the system is configured to have EMG sensing capability during re- programming, which can be particularly valuable.
- Stimulation levels during re-programming are typically low to avoid patient discomfort which often results in difficult generation of motor responses. Involuntary muscle movement while the patient is awake may also cause noise that is difficult for the physician to differentiate.
- EMG allows the clinician to detect motor responses at very low stimulation levels (e.g., sub-threshold), and help them distinguish a motor response originated by sacral nerve stimulation from involuntary muscle movement.
- the stimulation cable set consists of one stimulation mini-clip 3 and one ground patch 5. It is used with a foramen needle 1 to locate the sacral nerve and verify the integrity of the nerve via test stimulation. Another stimulation cable set with four stimulation channels 2 is used to verify the lead position with a tined stimulation lead 20 during the staged trial. Both cable sets are sterilizable as they will be in the sterile field.
- a total of five over-the-shelf sensing electrode patches 4 e.g., two sensing electrode pairs for each sensing spot and one common ground patch) are provided for EMG sensing at two different muscle groups (e.g., perineal musculature and big toe) simultaneously during the lead placement procedure.
- the clinician programmer 60 allows the clinician to read the impedance of each electrode contact whenever the lead is connected to an EPG, an IPG or a clinician programmer to ensure reliable connection is made and the lead is intact. In some embodiments, any electrode with unacceptable impedance can be locked out from being assigned as an anode or cathode.
- Unacceptable impedance can be impedance less than 50 or greater than 3,000 Ohms, or alternatively less than 500 or greater than 5,000 Ohms.
- the clinician programmer 60 is also able to save and display previous (e.g., up to the last four) programs that were used by a patient to help facilitate re-programming.
- the clinician programmer 60 further includes a USB port for saving reports to a USB drive and a charging port.
- the clinician programmer may also include physical on/off buttons to turn the clinician programmer on and off and/or to turn stimulation on and off.
- the IPG may be configured with two stimulation modes: continuous mode and cycling mode, such as shown in FIG. 7.
- the cycling mode saves energy in comparison to the continuous mode, thereby extending the recharge interval of the battery and lifetime of the device.
- the cycling mode may also help reduce the risk of neural adaptation for some patients. Neural adaptation is a change over time in the responsiveness of the neural system to a constant stimulus. Thus, cycling mode may also mitigate neural adaptation so to provide longer-term therapeutic benefit.
- FIG. 7 shows an example of stimulation in a cycling mode, in which the duty cycle is the stimulation on time over the stimulation-on time plus the stimulation-off time.
- the IPG/EPG is configured with a ramping feature, such as shown in the example of FIG. 8.
- the stimulation signal is ramped up and/or down between the stimulation-on and stimulation-off levels. This feature helps reduce the sudden "jolting” or “shocking" sensation that some patients might experience when the stimulation is initially turned on or at the cycle-on phase during the cycling mode. This feature is particularly of benefit for patients who need relative high stimulation settings and/or for patients who are sensitive to electrical stimulation.
- the patient remote (e.g. FIG. 1, element 70) is provided to allow a patient to adjust the stimulation level of the electrical pulse generator.
- the patient remote can be used to wirelessly communicate with and control either an EPG (e.g., during a trial phase) or an IPG (e.g., for a permanent neurostimulation system).
- different patient remotes can be provided to control the EPG and the IPG, whereas in other implementations, a single patient remote can be programmed or reprogrammed to control either an EPG or an IPG.
- a particular patient remote can be configured to link with and wirelessly communicate with only a single EPG or IPG so as to avoid patients altering the stimulation of others.
- the degree of adjustment permitted to the patient through the patient remote can be limited, such that while the patient can incrementally increase or decrease the therapy delivered by the pulse generator, and can turn stimulation on or off, the level of stimulation therapy by the pulse generator whenever the pulse generator is applying stimulation is maintained within a clinically effective combination of settings.
- the patient is given a straightforward and simple tool for situational control of the pulse generator and overall neurostimulation system, allowing for the use of different stimulation levels (including no stimulation when appropriate) while the patient is awake, while the patient is asleep, while the patient is engaged in specific activities, or in other situations.
- the patient remote can allow a patient to turn on and turn off the pulse generator, where turning off the pulse generator may be desirable for the patient when performing activities that may inadvertently interfere with, or be inadvertently interfered by, an active pulse generator and the nerves stimulated by the pulse generator.
- innervation of the S3 sacral nerve can cause a response in the plantar flexion of the great toe or other toes.
- the switches of the patient remote can instead be buttons, formed as part of the body of the patient remote, or formed to pass through shaped holes in the surface of the patient remote.
- the buttons can be spring biased or otherwise supported so as to provide a degree of resistance to actuation and/or to restore a button to a default status after actuation is completed and the button is released.
- Any given switch or button on the patient remote can be located within a depression of the external surface of the patient remote, on a flat surface of the external surface of the patient remote, or on a convex surface of the extemal surface of the patient remote.
- any given switch or button on the patient remote can have a profile that is flush with the extemal surface of the patient remote, elevated from the external surface of the patient remote, or inset/depressed within the external surface of the patient remote.
- a change in state can include a change in an activation state of the patient remote, or a mode of the pulse generator and a stimulation level of the IPG or EPG that is controlled by the patient remote.
- the actuation feature can be a button, lever, knob, or an optical or touch sensor or any suitable feature that allows a user to effect the change in state by interaction with the feature.
- the actuation features can include portions of a touch screen displayed to a user.
- the patient remote 900 can have an oblong, elongated, rectangular, spherical, square, ellipsoid, or irregular shape, or a combination thereof.
- the patient remote 900 can be constructed to be waterproof, where any structural seams of the portable housing 902 can have an airtight interface or sealed with an additional polymer or chemical compound.
- the portable housing 902 can further be designed to attach as a fob device, configured to be carried daily, having a mechanical coupling structure 916 to attach the patient remote 900 with a key ring, karabiner, or other such mounting element.
- the patient remote 900 can include within the interior of the portable housing 902 transmission circuitry configured to interface with the pulse generator, a battery that functions as a power source for the patient remote, and control electronics. Control electronics in the interior of the portable housing 902 can be operatively coupled to relay signals to the transmission circuitry for controlling control the pulse generator corresponding to actuation of the one or more switches disposed on the exterior surface of the portable housing 902.
- the patient remote 900 can include circuitry to communicate with the clinician programmer (CP).
- the transmission circuitry can include a radio frequency (RF) transmitter that communicates with other system elements on the Medical Implant Communication Service (MICS) frequency band (MedRadio 402-405 MHz).
- RF radio frequency
- MIMS Medical Implant Communication Service
- the wireless communication between the patient remote 900 and the pulse generator to which the patient remote 900 sends instructions can have an operational range of up to three feet, in addition to transmission through the tissue of a patient, in embodiments where the pulse generator is an IPG implanted in the patient.
- a patient remote 900 having any or all of an activation switch 904, stimulation-increase switch 906, or stimulation-decrease switch 908 (where any or all of activation switch 904, stimulation-increase switch 906, or stimulation-decrease switch 908 can be buttons) disposed on the exterior surface of the portable housing 902 can be configured such that actuation of such switches and/or buttons (where actuation can be depressing, triggering, toggling, or otherwise operating the switch or button) causes the control electronics and/or transmission circuitry of the patient remote 900 to relay a signal to a neurostimulation system and/or to execute a function of the patient remote 900 itself.
- the battery that powers the patient remote 900 can be a permanent battery having an operational life of three or more years.
- the battery that powers the patient remote 900 can be a replaceable or a rechargeable battery.
- the activation switch 904 (alternatively referred to as a "link switch") can be disposed on the control surface 903, and in particular embodiments the activation switch 904 can be disposed in a recessed region of the control surface 903. In embodiments where the activation switch 904 is disposed in a recess of the control surface 903, activation switch 904 is designed to be actuation due to deliberate effort.
- the activation switch 904 is recessed so as to avoid accidental depression by the user when the patient remote 900 is stored in a pocket or purse of the patient.
- the recess can have a sufficient depth relative to the size of the activation switch 904 such that the height of the activation switch 904 is shorter than the depth of the recess, and thus the activation switch 904 does not extend out of the recess.
- the activation switch 904 operates to switch the patient remote 900 between an asleep mode and an awake mode. When the patient remote 900 is in an asleep mode, actuation of the activation switch 904 causes the patient remote to switch to the awake mode and to interrogate the neurostimulator to wirelessly retrieve data regarding the status of the neurostimulation system and/or pulse generator.
- the data retrieved from the neurostimulation system can include the current stimulation level of the pulse generator, which can be stored in a processor and/or memory of the pulse generator.
- actuation of the activation switch 904 causes the patient remote 900 to switch to the asleep mode.
- the stimulation-increase switch 906 and the stimulation-decrease switch 908 are inactivated, such that actuation of either the stimulation-increase switch 906 or the stimulation-decrease switch 908 does not cause the patient remote 900 to send any signal with transmission circuitry within the portable housing 902.
- the stimulation-increase switch 906 and the stimulation-decrease switch 908 are active, such that actuation of either the stimulation-increase switch 906 or the stimulation-decrease switch 908 causes the patient remote 900 to send a corresponding instruction signal with transmission circuitry within the portable housing 902.
- the patient remote 900 can automatically switch to the asleep mode.
- the set period of time after which the patient remote 900 will automatically switch to the asleep mode can be five (5) to sixty (60) seconds, or any increment or gradient of time within that range. In specific aspects, the set period of time after which the patient remote 900 will automatically switch to the asleep mode can be ten (10) seconds.
- the control surface 903 can include a stimulation-increase switch 906 coupled to control electronics and transmission circuitry disposed within the portable housing 902. Actuation of the stimulation-increase switch 906 can relay an instruction signal to the pulse generator (i.e., through the control electronics and transmission circuitry of the patient remote 900), where the instruction signal can be selected based on duration of time that the stimulation-increase switch 906 is actuated.
- the stimulation-increase switch 906 is actuated for a first period of time
- the patient remote 902 can send an instruction signal to the pulse generator to incrementally increase the stimulation level of the pulse generator.
- the first period of time will generally be a period of time that is shorter than a threshold.
- shocking sensation that some patients might experience when the stimulation is turned on.
- the previously stored stimulation level can be the last stimulation level the pulse generator was set to before turning off the neurostimulation system.
- the data indicating the last stimulation level can be stored in a memory of the pulse generator which is retrieved by the patent remote 900 when the patient remote 900 switches from the asleep mode to the awake mode.
- the stimulation level can be stored in a memory of the circuitry within the patient remote 900 portable housing 902.
- the stimulation-increase switch 906 can further have a visible and/or tactile surface or feature shaped to indicate to an operator that the stimulation-increase switch 906 is configured to increase or restore the stimulation level of the pulse generator (e.g., as an upward arrow, as a plus sign, etc.).
- the stimulation-increase switch 906 can be relatively larger than any stimulation-decrease switch 908 also disposed on the exterior of the portable housing 902.
- the control surface 903 can also include a stimulation-decrease switch 908 coupled to control electronics and transmission circuitry disposed within the portable housing 902. Actuation of the stimulation-decrease switch 908 can relay an instruction signal to the pulse generator, where the instruction signal can be selected based on duration of time that the stimulation-decrease switch 908 is actuated.
- the patient remote 902 can send a signal to the pulse generator incrementally decrease the stimulation level of the pulse generator, with the time period for a longer switch actuation threshold time being sufficient to assure that the longer duration switch actuation is clearly intentional, typically being three seconds or more.
- actuation of the stimulation-decrease switch 908 for the first period of time can turn off stimulation by the pulse generator.
- the stimulation-decrease switch 908 is actuated for a second period of time, the patient remote 902 can send a signal to the pulse generator to store the status of the current stimulation level in a memory and turn off stimulation by the pulse generator.
- the second period of time can be three seconds or more.
- the pulse generator can gradually ramp down (as shown in FIG. 8) to a zero stimulation status.
- the stimulation-decrease switch 908 can further have a visible and/or tactile surface or feature shaped to indicate to an operator that the stimulation-decrease switch 908 is configured to decrease the stimulation level of the pulse generator or turn off stimulation by the pulse generator (e.g., as a downward arrow, as a minus sign, etc.).
- the memory in which the stimulation level is stored in the patient remote, or alternately the memory may be stored in the pulse generator.
- the stimulation-increase switch 906 and the stimulation-decrease switch 908 can be relatively equal in size.
- each incremental change can be five percent (5%), more than five percent
- a pulse generator is delivering treatment at a stimulation level of 2.0 mA
- a single step up increasing the stimulation level can be 0.2 mA (10% of 2.0 mA), thereby increasing stimulation to 2.2 mA.
- a subsequent step up increasing the stimulation level can be 0.22 mA (10% of 2.2 mA), thereby increasing stimulation to 2.42 mA.
- a pulse generator is delivering treatment at a stimulation level of 4.0 mA
- a single step down decreasing the stimulation level can be 0.4 mA (10% of 4.0 mA), thereby decreasing stimulation to 3.6 mA.
- the step size by which the pulse generator stimulation level is changed can be 1% to 25% of the existing stimulation level, or any increment or gradient of a percentage within that range.
- the number of available treatment levels may be between 3 and 15, typically being between 4 and 10, and often being between 5 and 8.
- a single step up increasing the stimulation level can be ten percent of the baseline stimulation, 0.3 mA (10% of 3.0 mA), thereby increasing stimulation to 3.3 mA.
- a subsequent step up increasing the stimulation level can also be based on the baseline stimulation level, that step again being 0.3 mA, thereby increasing stimulation to 3.6 mA.
- a single step down decreasing stimulation from a baseline level of 3.0 mA can lower the current stimulation level to 2.7 mA, and a subsequent step down can decrease the current stimulation level to 2.4 mA.
- each step of stimulation level can be based on a percentage of a maximum stimulation level. For example, if a pulse generator has a maximum treatment stimulation level of 4.0 mA, each step of stimulation level change can be ten percent of the maximum stimulation level, 0.4 mA (10% of 4.0 mA). Thus, relative to the maximum stimulation level, a single step down decreasing the stimulation level can be at 3.6 mA, a subsequent step down decreasing the stimulation level can be at 3.2 mA, and so forth.
- the patient remote 900 can operate having an automated proportional stimulation step level increments.
- the incremental steps can be smaller than those associated with a higher amplitude range.
- the default increment for a step of simulation level can be 0.05 mA.
- the default increment for a step of simulation level can be 0.10 mA.
- the default increment for a step of simulation level can be 0.20 mA.
- the proportional change in stimulation level step can be varied depending on the amount of treatment required, the number of amplitude ranges, the breadth of amplitude ranges, and/or according to other factors controlling the operation of the patient remote 900.
- the above described incremental steps can also be applied when determining electrode thresholds during electrode characterization and/or programming.
- the patient remote 900 can be set to incrementally adjust stimulation by a step-size defined by a relationship between a maximum stimulation level (Im a x) and a baseline, also referred to as a nominal or normal stimulation level (I n ).
- Im a x a maximum stimulation level
- I n a nominal or normal stimulation level
- the I max and the I n can be determined and set-up by a physician programming the patient remote 900 via the clinician programmer.
- the amplitude of Im a x can be set according to the comfort level of a patient (e.g. stimulation level just below where any pain or discomfort is reported by the patient).
- the increment step size can be a set proportion or percentage of ⁇ , for example steps sizes of 1 ⁇ 2 ⁇ , 1 ⁇ 2 ⁇ , or 1 ⁇ 4 ⁇ .
- the CP automatically sets such an incremental step size (e.g. 1 ⁇ 2 ⁇ ) with the IPG or EPG, for example during electrode characterization and/or programming.
- patient remote 900 can be programmed with a step-size that corresponds to the step-size used by the CP in programming the IPG or EPG.
- the amount by which the stimulation levels can be adjusted below the nominal stimulation level e.g. lower range
- the amount by which the stimulation levels can be adjusted below the nominal stimulation level can be defined to mirror the incremental range between ⁇ and I n (e.g. upper range).
- the range over which the stimulation level can be incrementally adjusted by the patient remote includes seven stimulation levels, where the nominal or normal stimulation level I n is in the middle of those seven stimulation levels, incrementing up or down at 1 ⁇ 2 ⁇ per step allows for a range of stimulation levels that reaches the maximum stimulation level I max on one end of the available treatment range, and a minimum stimulation level that mirrors Im a x on the other end of the available treatment range, as shown below:
- the command can include the step-size by which the stimulation level is adjusted or the command can invoke an incremental adjustment based on a step-size increment stored on a memory of the pulse generator.
- the patient remote 900 can increase and/or decrease the stimulation level by a predetermined percentage.
- the predetermined percentage is a set percentage within a range between 5% and 20%, such as about 10% (+/- 2%).
- the predetermined percentage is the same for incremental increases and decreases, while in other embodiments, the increase increment differs from that of the decrease increment.
- the control surface 903 can include a stimulation-level display 910 embedded in the portable housing 902, and electronically coupled to control electronics and transmission circuitry disposed within the portable housing 902 such that the stimulation-level display 910 can indicate the stimulation level being delivered by the pulse generator to a patient.
- the stimulation-level display 910 can include a plurality of lights or light emitting diodes (LEDs) arranged on the control surface, where an illuminated subset of the total number of the plurality of lights or LEDs can indicate the current stimulation level of the pulse generator.
- the stimulation-level display 910 can include seven (7) white-light LEDs.
- the stimulation-level display 910 can have the plurality of LEDs arranged in a pattern to reflect increases and decreases to the stimulation level of the pulse generator.
- a first LED 910-1 can indicate that the pulse generator is set to deliver a stimulation level at the minimum power selectable via the patient remote 900.
- a second LED 910-2, a third LED 910-3, a fourth LED 910-4, a fifth LED 910-5, and a sixth LED 910-6 can indicate (as read from left to right, optionally with all of the lower-level LEDs remaining illuminated as stimulation level increases) progressively increasing power of stimulation levels selectable via the patient remote 900 that the pulse generator is set to deliver.
- illumination of a seventh LED 910-7 can indicate (optionally with all other stimulation-level LEDs also being illuminated) that the pulse generator is set to deliver a stimulation level at the maximum power selectable via the patient remote 900.
- the stimulation-level display 910 can include green-light, amber-light, or other colored-light LEDs, which can also provide a relative qualitative indication of the power of each stimulation level of the pulse generator.
- the LEDs used for the stimulation-level display 910 can be of at least three (3) or four (4) varying sizes to provide a relative qualitative indication of the power of each stimulation level of the pulse generator. In other words, relatively smaller LEDs can be used for the stimulation levels closer or trending toward the minimum power selectable via the patient remote 900 and relatively larger LEDs can be used for the stimulation levels closer or trending toward the maximum power selectable via the patient remote 900.
- a patient remote 900 can be configured to be used with any appropriate respective pulse generator, such that the patient remote 900 can link with and wirelessly communicate with only a single EPG or IPG, so as to avoid inadvertent and unintentional activation, alteration, or triggering of stimulation of other pulse generators.
- a specific patient remote 900 can be paired with a specific pulse generator (e.g., an IPG, an EPG, or the like) such that the patient remote 900 will only, or at least primarily, operate to interact with the paired pulse generator.
- FIGS. 9-1 to 9-7 are schematic illustrations of a patient remote showing an increasing progression of stimulation levels by the stimulation-level display 910 LEDs.
- the patient remote 900 can illuminate only the LED indicating that specific stimulation level.
- the available stimulation levels of the pulse generator can be programmed relative to a baseline stimulation level, and the patient remote 900 can be configured provide a limited range of selectable stimulation levels either greater than and/or less than the baseline stimulation level, and ideally both.
- the baseline stimulation level can be selected to correspond to illuminate any one of a plurality of LEDs for the stimulation-level display 910, which can further indicate the number of selectable stimulation levels greater than and less than the baseline stimulation level.
- the pulse generator can be programmed to have three selectable stimulation levels greater than the baseline stimulation level and three selectable stimulation levels less than the baseline stimulation level. In such embodiments, when the pulse generator is set to the baseline stimulation level, the fourth
- the pulse generator can be programmed to have four selectable stimulation levels greater than the baseline stimulation level and two selectable stimulation levels less than the baseline stimulation level. In such embodiments, when the pulse generator is set to the baseline stimulation level, the third LED 910-3 of the patient remote 900 is illuminated (optionally along with first and second LEDs). In alternative aspects, the pulse generator can be programmed such that at the baseline stimulation level, one of the second LED 910-2, the fifth LED 910-5, or the sixth LED 910-6 on the patient remote 900 is illuminated, with corresponding selectable stimulation levels greater than and less than the baseline stimulation level.
- the baseline stimulation level can be selected to ensure that any adjustment to the therapy via the patient remote remains within a clinically effective range whenever stimulation is applied.
- the clinically effective range of stimulation by the pulse generator can be from about 0.5 mA to about 4 mA.
- the clinically effective range of stimulation by the pulse generator can be from about 1 mA to about 3 mA.
- the ideal clinically effective range of stimulation by the pulse generator can be from about 0.3 mA to about 2.5 mA, while further for such aspects, stimulation by the pulse generator that is less than 0.3 mA and between from about 2.5 mA to about 4 mA can also be clinically effective at providing treatment. In some embodiments, stimulation is limited to below 4 mA.
- electrodes with stimulation thresholds that provide a desired parameter e.g. sensory or motor response
- electrodes with a threshold between 0.3 - 2.5 mA can be considered preferred electrodes for use in neurostimulation therapy delivery
- electrodes with thresholds less than 0.3 mA and between 2.5 - 4 mA can be considered acceptable
- electrodes with thresholds greater than 4 mA can be considered unacceptable for delivering neurostimulation.
- these ranges are an example that is applicable to certain embodiments and certain therapies (e.g. sacral neuromodulation for treatment of OAB and fecal incontinence) and that various other ranges can apply to various other neurostimulation systems and/or therapies.
- the baseline stimulation level can be selected to have (1) a pulse amplitude or power within the clinically effective range and (2) a proportional incremental change for increasing or decreasing stimulation relative to the baseline stimulation level such that, at either the maximum or minimum stimulation level selectable via the patient remote, the therapy delivered by the pulse generator remains within the clinically effective range.
- the clinically effective range of the pulse generator can include pulses having a pulse amplitude in a range between 0 mA to 1,000 mA, 0 mA to 100 mA, 0 mA to 50 mA, or 0 mA to 25 mA.
- the pulse generator can be programmed to have a baseline stimulation of 2.0 mA with three selectable stimulation levels greater than the baseline stimulation level and three selectable stimulation levels less than the baseline stimulation level, where each step of adjustment can be ten percent (10%) of the existing or current stimulation level.
- the baseline stimulation level of 2.0 mA is represented in the stimulation-level display 910 by the fourth LED 910-4 being illuminated
- the minimum stimulation level selectable by the patient remote 900 is 1.458 mA (represented by the first LED 910-1 being illuminated)
- the maximum stimulation level selectable by the patient remote 900 is 2.662 mA (represented by the seventh LED 910-7 being illuminated).
- the pulse generator can be programmed to have a baseline stimulation of 2.0 mA with four selectable stimulation levels greater than the baseline stimulation level and two selectable stimulation levels less than the baseline stimulation level, where each step of adjustment can be ten percent (10%) of the existing or current stimulation level.
- the baseline stimulation level of 2.0 mA is represented in the stimulation-level display 910 by the third LED 910-3 being illuminated
- the minimum stimulation level selectable by the patient remote 900 is 1.62 mA (represented by the first LED 910-1 being illuminated)
- the maximum stimulation level selectable by the patient remote 900 is 2.9282 mA (represented by the seventh LED 910-7 being illuminated).
- FIGS. 9-8 and 9-9 are schematic illustrations of a patient remote 900 with a therapy- remaining display 912 showing levels of therapy remaining for a neurostimulation system.
- the therapy-remaining display 912 can be an LED indicator capable of emitting one or more colors of light.
- the therapy -remaining display 912 is shown emitting a green light 913g (as represented by the solid-line wavefront illustration).
- the therapy- remaining display 912 is shown emitting an amber light 913a (as represented by the broken- line wavefront illustration).
- the therapy -remaining display 912 can disposed on the exterior surface of the portable housing 902, such as on the control surface 903.
- the therapy -remaining display 912 can illuminate with a constant (non- flashing) emission of light, or can illuminate in a flashing or intermittent mode.
- the therapy -remaining display 912 is a bi- color LED
- the color of light emitted by the therapy -remaining display 912 and whether the light is emitted as constant or flashing can provide an observer with a qualitative indication of how much therapy and/or battery life is remaining in a neurostimulation system pulse generator.
- the therapy-remaining display 912 can emit a green light 913g when the pulse generator rechargeable battery has at least thirty percent (> 30%) of its charge capacity remaining, which can corresponds to at least four (> 4) days of nominal stimulation remaining in the neurostimulation system. Further in this
- the therapy -remaining display 912 can emit a constant amber light 913a when the pulse generator battery has more than fifteen percent (> 15%) but less than thirty percent ( ⁇ 30%) of its charge capacity remaining, which can corresponds to about two to four (2-4) days of nominal stimulation remaining in the neurostimulation system.
- the therapy - remaining display 912 emitting a constant amber light 913a can be an indication to the patient that the pulse generator battery is relatively low on charge and requires recharging within the subsequent 2-4 days.
- the therapy -remaining display 912 can emit a flashing amber light 913a when the pulse generator battery has less than fifteen percent ( ⁇ 15%) its charge capacity remaining.
- the amount of charge capacity will vary from battery to battery for any pulse generator or neurostimulation system.
- the rechargeable battery can have a charge capacity such that 30% of the charge capacity is about 3.55 Volts and 15% of the charge capacity is about 3.45 Volts, where the therapy-remaining display 912 can emit a constant or flashing green light 913g or a constant or flashing amber light 913a as appropriate relative to such voltages.
- the amount of therapy remaining for a neurostimulation system and pulse generator is dependent at least on the duration of usage of the neurostimulation system and the level of stimulation the neurostimulation system is instructed to deliver.
- a processor coupled to the pulse generator can calculate the amount of therapy remaining in a pulse generator based on factors including, but not limited to, the overall capacity of the pulse generator rechargeable battery, the amount of time elapsed since the pulse generator rechargeable battery was last recharged, the average stimulation level at which the pulse generator is operated, the median stimulation level at which the pulse generator is operated, the current voltage of the battery, and the like.
- the visual indicators of the patient remote 900 can be augmented with a haptic or vibratory feedback that punctuates adjustments to stimulation level, where a vibrating element (e.g., a motor, a piezoelectric, etc.) is disposed within the interior of the portable housing 902.
- the vibrating element can be configured to activate when the pulse generator confirms that an instruction from the patient remote 900 has been received and executed.
- Such commands from the patient remote can include, but are not limited to, turning on the pulse generator, turning off the pulse generator increasing the stimulation level of the pulse generator, or decreasing the stimulation level of the pulse generator.
- the vibration element can also be configured to activate for situations including, but not limited to, the patient remote 900 switching from the asleep mode to the awake mode or providing a warning that the rechargeable pulse generator battery has a low charge.
- the patient remote 900 such as the stimulation-level display 910, the therapy -remaining display 912, and the vibration element, and interpretations of the feedback from the indicators.
- Table 3 Patient Remote Indicators and Feedback
- fault condition indicator 914 can cause the fault condition indicator 914 to illuminate include, but are not limited to, failure of the pulse generator to respond to commands from the patient remote 900, a low charge for the battery operating the patient remote 900, where fault conditions are of the type common to active implantable devices, which for example may be one or more of low patient remote battery, patient remote software or hardware fault, pulse generator hardware or software fault, and impedance out of range.
- the portable housing 902 can have a mechanical coupling structure 916 to attach the patient remote 900 with a key ring, karabiner, or other such mounting element.
- the mechanical coupling structure 916 can be embedded in the structure of the portable housing 902 or looped around a portion of the portable housing 902.
- FIG. 10 is a functional block diagram of components of a patient remote 1000.
- the patient remote 1000 encloses a battery 1002, control electronics 1004, transmission circuitry 1006, and a bus structure 1008 to allow for communication and transmission of power between the components of the patient remote 1000.
- the patient remote also optionally includes a memory 1010 for storing of data, such as the stimulation status of a linked neurostimulation system.
- the control electronics 1004 also includes locations where the control electronics 1004 can couple with an activation switch 1012, a stimulation-increase switch 1014, and a stimulation-decrease switch 1016.
- the bus 1008 can further communicate with a stimulation level display 1018, a therapy -remaining- display 1020, a vibration motor 1022, and a fault condition indicator 1024.
- the optional memory 1010 of the patient remote 1000 can store a previous or last stimulation level at which a pulse generator (e.g., an IPG or EPG) paired to the patient remote 1000 was operating.
- a pulse generator e.g., an IPG or EPG
- the previous or last stimulation level at which a pulse generator paired to the patient remote 1000 was operating can be stored within data memory of the pulse generator, respectively.
- the status or condition of the pulse generator can be transmitted to the transmission circuitry 1006 of the patient remote 1000 upon interrogation of the pulse generator when the patient remote 1000 is triggered into an awake mode.
- the status or condition of the pulse generator can be conveyed to the control electronic 1004 of the patient remote to allow for control of the pulse generator via the patient remote based upon the relevant stimulation level of the pulse generator.
- the transmission of data between a pulse generator and the patient remote can be wireless, and can further be set at a predetermined radio frequency (RF) for a paired set of a patient remote and pulse generator.
- RF radio frequency
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017536020A JP6805153B2 (en) | 2015-01-09 | 2016-01-11 | How to use with patient remote devices and associated neurostimulation systems |
EP16735557.7A EP3242712B1 (en) | 2015-01-09 | 2016-01-11 | Patient remote and associated methods of use with a nerve stimulation system |
CN201680015091.3A CN107427675B (en) | 2015-01-09 | 2016-01-11 | Patient remote control and associated method for use with a neurostimulation system |
ES16735557T ES2725489T3 (en) | 2015-01-09 | 2016-01-11 | Remote patient control and use procedures associated with a nervous stimulation system |
AU2016205047A AU2016205047B2 (en) | 2015-01-09 | 2016-01-11 | Patient remote and associated methods of use with a nerve stimulation system |
CA2973190A CA2973190A1 (en) | 2015-01-09 | 2016-01-11 | Patient remote and associated methods of use with a nerve stimulation system |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562101666P | 2015-01-09 | 2015-01-09 | |
US62/101,666 | 2015-01-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016112398A1 true WO2016112398A1 (en) | 2016-07-14 |
Family
ID=56356545
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2016/012918 WO2016112398A1 (en) | 2015-01-09 | 2016-01-11 | Patient remote and associated methods of use with a nerve stimulation system |
Country Status (8)
Country | Link |
---|---|
US (5) | US9895546B2 (en) |
EP (1) | EP3242712B1 (en) |
JP (1) | JP6805153B2 (en) |
CN (1) | CN107427675B (en) |
AU (1) | AU2016205047B2 (en) |
CA (1) | CA2973190A1 (en) |
ES (1) | ES2725489T3 (en) |
WO (1) | WO2016112398A1 (en) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9564777B2 (en) | 2014-05-18 | 2017-02-07 | NeuSpera Medical Inc. | Wireless energy transfer system for an implantable medical device using a midfield coupler |
US9610457B2 (en) | 2013-09-16 | 2017-04-04 | The Board Of Trustees Of The Leland Stanford Junior University | Multi-element coupler for generation of electromagnetic energy |
US10105542B2 (en) | 2015-01-09 | 2018-10-23 | Axonics Modulation Technologies, Inc. | Patient remote and associated methods of use with a nerve stimulation system |
US10589089B2 (en) | 2017-10-25 | 2020-03-17 | Epineuron Technologies Inc. | Systems and methods for delivering neuroregenerative therapy |
EP3900778A1 (en) * | 2020-04-23 | 2021-10-27 | ONWARD Medical B.V. | A neuromodulation system for planning and/or adjusting and/or providing a neuromodulation therapy |
US11247045B2 (en) | 2017-10-25 | 2022-02-15 | Epineuron Technologies Inc. | Systems and methods for delivering neuroregenerative therapy |
US11247043B2 (en) | 2019-10-01 | 2022-02-15 | Epineuron Technologies Inc. | Electrode interface devices for delivery of neuroregenerative therapy |
US11338148B2 (en) | 2015-05-15 | 2022-05-24 | NeuSpera Medical Inc. | External power devices and systems |
WO2022187471A1 (en) * | 2021-03-04 | 2022-09-09 | Inspire Medical Systems, Inc. | Assemblies and methods for wirelessly interfacing with an implantable medical device |
WO2022261001A1 (en) * | 2021-06-07 | 2022-12-15 | Boston Scientific Neuromodulation Corporation | Stimulation systems with user-specified routines and methods of making and using |
US11672983B2 (en) | 2018-11-13 | 2023-06-13 | Onward Medical N.V. | Sensor in clothing of limbs or footwear |
US11672982B2 (en) | 2018-11-13 | 2023-06-13 | Onward Medical N.V. | Control system for movement reconstruction and/or restoration for a patient |
WO2023115132A1 (en) * | 2021-12-23 | 2023-06-29 | Saluda Medical Pty Ltd | Assisted programming system for neural stimulation therapy |
US11691015B2 (en) | 2017-06-30 | 2023-07-04 | Onward Medical N.V. | System for neuromodulation |
US11717689B2 (en) | 2018-04-19 | 2023-08-08 | Iota Biosciences, Inc. | Implants using ultrasonic communication for neural sensing and stimulation |
US11752342B2 (en) | 2019-02-12 | 2023-09-12 | Onward Medical N.V. | System for neuromodulation |
US11839766B2 (en) | 2019-11-27 | 2023-12-12 | Onward Medical N.V. | Neuromodulation system |
US11848090B2 (en) | 2019-05-24 | 2023-12-19 | Axonics, Inc. | Trainer for a neurostimulator programmer and associated methods of use with a neurostimulation system |
US11890474B2 (en) | 2018-04-19 | 2024-02-06 | Iota Biosciences, Inc. | Implants using ultrasonic communication for modulating splenic nerve activity |
US11957910B2 (en) | 2011-01-03 | 2024-04-16 | California Institute Of Technology | High density epidural stimulation for facilitation of locomotion, posture, voluntary movement, and recovery of autonomic, sexual, vasomotor, and cognitive function after neurological injury |
US11969596B2 (en) | 2018-08-29 | 2024-04-30 | Iota Biosciences, Inc. | Implantable closed-loop neuromodulation device, systems, and methods of use |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013111137A2 (en) | 2012-01-26 | 2013-08-01 | Rainbow Medical Ltd. | Wireless neurqstimulatqrs |
WO2014087337A1 (en) | 2012-12-06 | 2014-06-12 | Bluewind Medical Ltd. | Delivery of implantable neurostimulators |
US10098585B2 (en) | 2013-03-15 | 2018-10-16 | Cadwell Laboratories, Inc. | Neuromonitoring systems and methods |
PL3003473T3 (en) | 2013-05-30 | 2019-05-31 | Neurostim Solutions LLC | Topical neurological stimulation |
US11229789B2 (en) | 2013-05-30 | 2022-01-25 | Neurostim Oab, Inc. | Neuro activator with controller |
US10398369B2 (en) | 2014-08-08 | 2019-09-03 | Medtronic Xomed, Inc. | Wireless stimulation probe device for wireless nerve integrity monitoring systems |
CN107427685B (en) * | 2015-01-09 | 2021-09-21 | 艾克索尼克斯股份有限公司 | Attachment devices for use with neurostimulation charging devices and associated methods |
US11077301B2 (en) | 2015-02-21 | 2021-08-03 | NeurostimOAB, Inc. | Topical nerve stimulator and sensor for bladder control |
US10039915B2 (en) | 2015-04-03 | 2018-08-07 | Medtronic Xomed, Inc. | System and method for omni-directional bipolar stimulation of nerve tissue of a patient via a surgical tool |
KR101656723B1 (en) * | 2015-06-30 | 2016-09-12 | 재단법인 오송첨단의료산업진흥재단 | Feedthrough making method |
US10105540B2 (en) | 2015-11-09 | 2018-10-23 | Bluewind Medical Ltd. | Optimization of application of current |
US10445466B2 (en) | 2015-11-18 | 2019-10-15 | Warsaw Orthopedic, Inc. | Systems and methods for post-operative outcome monitoring |
US10339273B2 (en) | 2015-11-18 | 2019-07-02 | Warsaw Orthopedic, Inc. | Systems and methods for pre-operative procedure determination and outcome predicting |
USD797949S1 (en) * | 2016-02-12 | 2017-09-19 | Axonics Modulation Technologies, Inc. | Patient remote |
US9955882B2 (en) | 2016-08-31 | 2018-05-01 | Medtronic Xomed, Inc. | System to monitor neural integrity |
US10849517B2 (en) | 2016-09-19 | 2020-12-01 | Medtronic Xomed, Inc. | Remote control module for instruments |
US10124178B2 (en) | 2016-11-23 | 2018-11-13 | Bluewind Medical Ltd. | Implant and delivery tool therefor |
US9935395B1 (en) | 2017-01-23 | 2018-04-03 | Cadwell Laboratories, Inc. | Mass connection plate for electrical connectors |
US20180353764A1 (en) | 2017-06-13 | 2018-12-13 | Bluewind Medical Ltd. | Antenna configuration |
EP3706856A4 (en) | 2017-11-07 | 2021-08-18 | Neurostim Oab, Inc. | Non-invasive nerve activator with adaptive circuit |
US11253182B2 (en) | 2018-05-04 | 2022-02-22 | Cadwell Laboratories, Inc. | Apparatus and method for polyphasic multi-output constant-current and constant-voltage neurophysiological stimulation |
US11443649B2 (en) | 2018-06-29 | 2022-09-13 | Cadwell Laboratories, Inc. | Neurophysiological monitoring training simulator |
DE102018210760A1 (en) * | 2018-06-29 | 2020-01-02 | Biotronik Se & Co. Kg | Display device for a programming device |
US20200337567A1 (en) * | 2019-04-24 | 2020-10-29 | BraveHeart Wireless Inc. | Systems and Methods of Arrhythmia Detection |
USD902417S1 (en) * | 2019-06-03 | 2020-11-17 | Axonics Modulation Technologies, Inc. | Patient remote |
EP3990100A4 (en) | 2019-06-26 | 2023-07-19 | Neurostim Technologies LLC | Non-invasive nerve activator with adaptive circuit |
US11712569B2 (en) | 2019-09-25 | 2023-08-01 | Medtronic, Inc. | System and methods of decreasing the directional sensitivity of axially aligned rechargeable implant |
US11770017B2 (en) | 2019-10-24 | 2023-09-26 | Medtronic, Inc. | Self tuning class D driver for maximum power factor in wireless recharger |
JP2023506713A (en) | 2019-12-16 | 2023-02-20 | ニューロスティム テクノロジーズ エルエルシー | Noninvasive nerve activator using booster charge delivery |
CN112473005A (en) * | 2020-11-17 | 2021-03-12 | 北京品驰医疗设备有限公司 | Implanted nerve stimulator |
US11400299B1 (en) | 2021-09-14 | 2022-08-02 | Rainbow Medical Ltd. | Flexible antenna for stimulator |
WO2023215420A1 (en) | 2022-05-04 | 2023-11-09 | Axonics, Inc. | Devices and methods for improved remote programming of implanted neurostimulation systems |
US11850057B1 (en) * | 2023-02-16 | 2023-12-26 | Neuralytix, Llc | Intraoperative neural monitoring method utilizing wavelet-based event detection |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1470432A (en) * | 1973-04-16 | 1977-04-14 | Vitatron Medical Bv | Apparatus for use in stimulating responses in a physiological system |
US20020068960A1 (en) * | 1999-03-24 | 2002-06-06 | Saberski Lloyd R. | Apparatus and methods for reducing pain and/or retraining muscles |
US20070055318A1 (en) * | 2005-09-08 | 2007-03-08 | Medtronic, Inc. | External presentation of electrical stimulation parameters |
US20070270921A1 (en) * | 2006-05-17 | 2007-11-22 | Ndi Medical, Inc. | Systems and methods for patient control of stimulation systems |
US20090234302A1 (en) * | 2008-03-13 | 2009-09-17 | Medtronic,Inc. | Medical device and medical instrument alignment |
WO2009137683A2 (en) * | 2008-05-07 | 2009-11-12 | Hoffman Ross G | Transcranial direct current stimulation apparatus and methods |
US20100114259A1 (en) * | 2006-05-18 | 2010-05-06 | Uroplasty, Inc. | Method and Apparatus for Stimulating a Nerve of a Patient |
US20100222847A1 (en) * | 2007-10-24 | 2010-09-02 | Medtronic, Inc. | Transmission of power source usage information over a network |
WO2010111321A2 (en) * | 2009-03-27 | 2010-09-30 | Medtronic, Inc. | Conditional electrical stimulation in response to physiological information for pelvic health |
US20100318159A1 (en) * | 2009-06-12 | 2010-12-16 | Boston Scientific Neuromodulation Corporation | Miniature remote controller for implantable medical device |
US20110144468A1 (en) * | 2004-06-10 | 2011-06-16 | Medtronic Urinary Solutions, Inc. | Systems and methods of neuromodulation stimulation for the restoration of sexual function |
US20120197338A1 (en) * | 2011-01-28 | 2012-08-02 | Medtronic, Inc. | Stimulation therapy including substantially simultaneous bilateral stimulation |
US20120215285A1 (en) * | 2011-02-21 | 2012-08-23 | Boston Scientific Neuromodulation Corporation | System for Communication with Implantable Medical Devices Using a Bridge Device |
US20130184773A1 (en) * | 2012-01-17 | 2013-07-18 | Imad Libbus | Vagus Nerve Neurostimulator With Multiple Patient-Selectable Modes For Treating Chronic Cardiac Dysfunction |
US20130261692A1 (en) * | 2012-03-27 | 2013-10-03 | Urologix Inc. | Neuromodulation system and related methods |
Family Cites Families (445)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US116862A (en) | 1871-07-11 | Improvement in brackets | ||
US108063A (en) | 1870-10-04 | Improvement in button-hooks and handkerchief-holders combined | ||
US3057356A (en) | 1960-07-22 | 1962-10-09 | Wilson Greatbatch Inc | Medical cardiac pacemaker |
US3348548A (en) | 1965-04-26 | 1967-10-24 | William M Chardack | Implantable electrode with stiffening stylet |
US3646940A (en) | 1969-07-15 | 1972-03-07 | Univ Minnesota | Implantable electronic stimulator electrode and method |
US3888260A (en) | 1972-06-28 | 1975-06-10 | Univ Johns Hopkins | Rechargeable demand inhibited cardiac pacer and tissue stimulator |
US3825015A (en) | 1972-12-14 | 1974-07-23 | American Optical Corp | Single catheter for atrial and ventricular stimulation |
US3824129A (en) | 1973-03-14 | 1974-07-16 | Mallory & Co Inc P R | Heart pacer rechargeable cell and protective control system |
US3902501A (en) | 1973-06-21 | 1975-09-02 | Medtronic Inc | Endocardial electrode |
US3970912A (en) | 1973-08-28 | 1976-07-20 | Hoffman Philip A | Battery charging circuit |
US3942535A (en) | 1973-09-27 | 1976-03-09 | G. D. Searle & Co. | Rechargeable tissue stimulating system |
US3939843A (en) | 1974-03-04 | 1976-02-24 | Medtronic, Inc. | Transvenous electrode |
US3995623A (en) | 1974-12-23 | 1976-12-07 | American Hospital Supply Corporation | Multipurpose flow-directed catheter |
US4019518A (en) | 1975-08-11 | 1977-04-26 | Medtronic, Inc. | Electrical stimulation system |
US4044774A (en) | 1976-02-23 | 1977-08-30 | Medtronic, Inc. | Percutaneously inserted spinal cord stimulation lead |
US4082097A (en) | 1976-05-20 | 1978-04-04 | Pacesetter Systems Inc. | Multimode recharging system for living tissue stimulators |
US4141365A (en) | 1977-02-24 | 1979-02-27 | The Johns Hopkins University | Epidural lead electrode and insertion needle |
US4166469A (en) | 1977-12-13 | 1979-09-04 | Littleford Philip O | Apparatus and method for inserting an electrode |
US4340062A (en) | 1978-11-06 | 1982-07-20 | Medtronic, Inc. | Body stimulator having selectable stimulation energy levels |
US4285347A (en) | 1979-07-25 | 1981-08-25 | Cordis Corporation | Stabilized directional neural electrode lead |
US4269198A (en) | 1979-12-26 | 1981-05-26 | Medtronic, Inc. | Body implantable lead |
DE3015260A1 (en) | 1980-04-21 | 1981-10-22 | Siemens AG, 1000 Berlin und 8000 München | ENDOCARD ELECTRODE ARRANGEMENT |
US4379462A (en) | 1980-10-29 | 1983-04-12 | Neuromed, Inc. | Multi-electrode catheter assembly for spinal cord stimulation |
US4721118A (en) | 1981-04-20 | 1988-01-26 | Cordis Leads, Inc. | Pervenous electrical pacing lead with foldable fins |
US4437475A (en) | 1981-08-28 | 1984-03-20 | Medtronic, Inc. | Transvenous cardiovascular integrated lead anchoring sleeve, protector, and permanent lead introducer stop gap |
DE3146182C2 (en) | 1981-11-21 | 1984-03-29 | Peter Dr. 7889 Grenzach-Wyhlen Osypka | Electrode arrangement for a cardiac pacemaker that can be inserted transvenously into the heart |
US4512351A (en) | 1982-11-19 | 1985-04-23 | Cordis Corporation | Percutaneous lead introducing system and method |
JPS59109958U (en) | 1983-01-13 | 1984-07-24 | アイシン精機株式会社 | Rotor for speed sensor |
US4558702A (en) | 1983-01-21 | 1985-12-17 | Cordis Corporation | Cardiac pacer having input/output circuit programmable for use with unipolar and bipolar pacer leads |
GB2142831B (en) | 1983-01-21 | 1987-02-11 | Jose Alexander Marchosky | Implantable hyperthermia device and system |
US4961422A (en) | 1983-01-21 | 1990-10-09 | Marchosky J Alexander | Method and apparatus for volumetric interstitial conductive hyperthermia |
US4800898A (en) | 1983-10-07 | 1989-01-31 | Cordis Corporation | Neural stimulator electrode element and lead |
US4654880A (en) | 1983-12-09 | 1987-03-31 | Minnesota Mining And Manufacturing Company | Signal transmission system |
US4550731A (en) | 1984-03-07 | 1985-11-05 | Cordis Corporation | Acquisition circuit for cardiac pacer |
US4662382A (en) | 1985-01-16 | 1987-05-05 | Intermedics, Inc. | Pacemaker lead with enhanced sensitivity |
US4722353A (en) | 1985-09-16 | 1988-02-02 | Intermedics, Inc. | Stabilizer for implantable electrode |
US4848352A (en) | 1987-02-13 | 1989-07-18 | Telectronics, N.V. | Method for cardiac pacing and sensing using combination of electrodes |
US4744371A (en) | 1987-04-27 | 1988-05-17 | Cordis Leads, Inc. | Multi-conductor lead assembly for temporary use |
US4957118A (en) | 1988-01-15 | 1990-09-18 | Jay Erlebacher | Electrode lead |
US4860446A (en) | 1988-02-16 | 1989-08-29 | Medtronic, Inc. | Medical electrical lead and method of manufacture |
US5052407A (en) | 1988-04-14 | 1991-10-01 | Mieczyslaw Mirowski | Cardiac defibrillation/cardioversion spiral patch electrode |
US4989617A (en) | 1989-07-14 | 1991-02-05 | Case Western Reserve University | Intramuscular electrode for neuromuscular stimulation system |
US5012176A (en) | 1990-04-03 | 1991-04-30 | Baxter International, Inc. | Apparatus and method for calorimetrically determining battery charge state |
JP2535243B2 (en) * | 1990-04-26 | 1996-09-18 | シャープ株式会社 | Low frequency therapy device |
JPH04125357A (en) | 1990-09-18 | 1992-04-24 | Aisin Aw Co Ltd | Automatic transmission |
CA2038160C (en) | 1991-03-13 | 1996-10-22 | Jiri K. Nor | Charging circuits for rechargeable batteries and cells |
US5255691A (en) | 1991-11-13 | 1993-10-26 | Medtronic, Inc. | Percutaneous epidural lead introducing system and method |
GB9211085D0 (en) | 1992-05-23 | 1992-07-08 | Tippey Keith E | Electrical stimulation |
US5257634A (en) | 1992-07-16 | 1993-11-02 | Angeion Corporation | Low impedence defibrillation catheter electrode |
US5676651A (en) | 1992-08-06 | 1997-10-14 | Electric Boat Corporation | Surgically implantable pump arrangement and method for pumping body fluids |
US5342408A (en) | 1993-01-07 | 1994-08-30 | Incontrol, Inc. | Telemetry system for an implantable cardiac device |
JP3384027B2 (en) | 1993-05-14 | 2003-03-10 | ソニー株式会社 | Charging method and charger |
US5864220A (en) | 1993-09-16 | 1999-01-26 | Chartec Laboratories A/S | Method and apparatus for controlling the charging of a rechargeable battery to ensure that full charge is achieved without damaging the battery |
US5439485A (en) | 1993-09-24 | 1995-08-08 | Ventritex, Inc. | Flexible defibrillation electrode of improved construction |
US5484445A (en) | 1993-10-12 | 1996-01-16 | Medtronic, Inc. | Sacral lead anchoring system |
SE9304031D0 (en) | 1993-12-03 | 1993-12-03 | Siemens Elema Ab | electrode System |
JPH07222370A (en) | 1994-01-28 | 1995-08-18 | Sanyo Electric Co Ltd | Charger with temperature sensor |
US6249703B1 (en) | 1994-07-08 | 2001-06-19 | Medtronic, Inc. | Handheld patient programmer for implantable human tissue stimulator |
US5571148A (en) | 1994-08-10 | 1996-11-05 | Loeb; Gerald E. | Implantable multichannel stimulator |
US6035237A (en) | 1995-05-23 | 2000-03-07 | Alfred E. Mann Foundation | Implantable stimulator that prevents DC current flow without the use of discrete output coupling capacitors |
US5702431A (en) | 1995-06-07 | 1997-12-30 | Sulzer Intermedics Inc. | Enhanced transcutaneous recharging system for battery powered implantable medical device |
US5690693A (en) | 1995-06-07 | 1997-11-25 | Sulzer Intermedics Inc. | Transcutaneous energy transmission circuit for implantable medical device |
US5712795A (en) | 1995-10-02 | 1998-01-27 | Alaris Medical Systems, Inc. | Power management system |
US6898454B2 (en) | 1996-04-25 | 2005-05-24 | The Johns Hopkins University | Systems and methods for evaluating the urethra and the periurethral tissues |
DE19623788A1 (en) | 1996-06-04 | 1997-12-11 | Biotronik Mess & Therapieg | Implantable stimulation device |
US6609031B1 (en) | 1996-06-07 | 2003-08-19 | Advanced Neuromodulation Systems, Inc. | Multiprogrammable tissue stimulator and method |
US5733313A (en) | 1996-08-01 | 1998-03-31 | Exonix Corporation | RF coupled, implantable medical device with rechargeable back-up power source |
US5713939A (en) | 1996-09-16 | 1998-02-03 | Sulzer Intermedics Inc. | Data communication system for control of transcutaneous energy transmission to an implantable medical device |
SE9604143D0 (en) | 1996-11-13 | 1996-11-13 | Pacesetter Ab | Implantable electrode cable |
US5741316A (en) | 1996-12-02 | 1998-04-21 | Light Sciences Limited Partnership | Electromagnetic coil configurations for power transmission through tissue |
US5735887A (en) | 1996-12-10 | 1998-04-07 | Exonix Corporation | Closed-loop, RF-coupled implanted medical device |
JP3954177B2 (en) | 1997-01-29 | 2007-08-08 | 日本碍子株式会社 | Bonding structure between metal member and ceramic member and method for manufacturing the same |
US8555894B2 (en) | 1997-02-26 | 2013-10-15 | Alfred E. Mann Foundation For Scientific Research | System for monitoring temperature |
US7460911B2 (en) | 1997-02-26 | 2008-12-02 | Alfred E. Mann Foundation For Scientific Research | System and method suitable for treatment of a patient with a neurological deficit by sequentially stimulating neural pathways using a system of discrete implantable medical devices |
US8684009B2 (en) | 1997-02-26 | 2014-04-01 | Alfred E. Mann Foundation For Scientific Research | System for determining relative distance(s) and/or angle(s) between at least two points |
US6208894B1 (en) | 1997-02-26 | 2001-03-27 | Alfred E. Mann Foundation For Scientific Research And Advanced Bionics | System of implantable devices for monitoring and/or affecting body parameters |
US5957965A (en) | 1997-03-03 | 1999-09-28 | Medtronic, Inc. | Sacral medical electrical lead |
CA2230930A1 (en) | 1997-04-25 | 1998-10-25 | Dale Gathergood | Exterior rear view mirror integral warning light |
US5871513A (en) | 1997-04-30 | 1999-02-16 | Medtronic Inc. | Centerless ground feedthrough pin for an electrical power source in an implantable medical device |
US6191365B1 (en) | 1997-05-02 | 2001-02-20 | General Science And Technology Corp | Medical devices incorporating at least one element made from a plurality of twisted and drawn wires |
US5871532A (en) | 1997-05-22 | 1999-02-16 | Sulzer Intermedics Inc. | Epicardial lead for minimally invasive implantation |
IT1292016B1 (en) | 1997-05-28 | 1999-01-25 | Valerio Cigaina | IMPLANT DEVICE PARTICULARLY FOR ELECTROSTIMULATION AND / OR ELECTRO-REGISTRATION OF ENDOABDOMINAL VISCERS |
AU753694B2 (en) | 1997-08-01 | 2002-10-24 | Advanced Bionics Corporation | Implantable device with improved battery recharging and powering configuration |
US5991665A (en) | 1997-09-18 | 1999-11-23 | Sulzer Intermedics Inc. | Self-cooling transcutaneous energy transfer system for battery powered implantable device |
US6138681A (en) | 1997-10-13 | 2000-10-31 | Light Sciences Limited Partnership | Alignment of external medical device relative to implanted medical device |
JP3887828B2 (en) | 1997-11-20 | 2007-02-28 | セイコーエプソン株式会社 | Electronics |
US6306100B1 (en) | 1997-12-16 | 2001-10-23 | Richard L. Prass | Intraoperative neurophysiological monitoring system |
US6169387B1 (en) | 1997-12-22 | 2001-01-02 | Lifecor, Inc. | Battery management apparatus for portable electronic devices |
DE19800416C2 (en) | 1998-01-08 | 2002-09-19 | Storz Karl Gmbh & Co Kg | Device for the treatment of body tissue, in particular soft tissue close to the surface, by means of ultrasound |
US6081097A (en) | 1998-01-19 | 2000-06-27 | Matsushita Electric Industrial Co., Ltd. | Method for charging lithium secondary battery |
US6305381B1 (en) | 1998-02-02 | 2001-10-23 | Medtronic Inc. | System for locating implantable medical device |
DE69830203T2 (en) | 1998-02-23 | 2006-01-12 | Medtronic, Inc., Minneapolis | IMPLANTABLE MEDICAL DEVICE WITH HIGH FREQUENCY INPUT FOR CHARGING THE ENERGY SOURCE |
US5902331A (en) | 1998-03-10 | 1999-05-11 | Medtronic, Inc. | Arrangement for implanting an endocardial cardiac lead |
JP3826407B2 (en) | 1998-03-24 | 2006-09-27 | セイコーエプソン株式会社 | Electronic device, electronic device control method, secondary battery capacity estimation method, and secondary battery charge control method |
US6221513B1 (en) | 1998-05-12 | 2001-04-24 | Pacific Coast Technologies, Inc. | Methods for hermetically sealing ceramic to metallic surfaces and assemblies incorporating such seals |
US6243608B1 (en) | 1998-06-12 | 2001-06-05 | Intermedics Inc. | Implantable device with optical telemetry |
US6735474B1 (en) | 1998-07-06 | 2004-05-11 | Advanced Bionics Corporation | Implantable stimulator system and method for treatment of incontinence and pain |
US6941171B2 (en) | 1998-07-06 | 2005-09-06 | Advanced Bionics Corporation | Implantable stimulator methods for treatment of incontinence and pain |
US6027456A (en) | 1998-07-10 | 2000-02-22 | Advanced Neuromodulation Systems, Inc. | Apparatus and method for positioning spinal cord stimulation leads |
US6104960A (en) | 1998-07-13 | 2000-08-15 | Medtronic, Inc. | System and method for providing medical electrical stimulation to a portion of the nervous system |
US6178353B1 (en) | 1998-07-27 | 2001-01-23 | Advanced Bionics Corporation | Laminated magnet keeper for implant device |
US7231254B2 (en) | 1998-08-05 | 2007-06-12 | Bioneuronics Corporation | Closed-loop feedback-driven neuromodulation |
US6083247A (en) | 1998-08-10 | 2000-07-04 | Medtronic, Inc. | Perpendicular atrial fixation/stimulation loop |
US6104957A (en) | 1998-08-21 | 2000-08-15 | Alo; Kenneth M. | Epidural nerve root stimulation with lead placement method |
DE19838137A1 (en) | 1998-08-21 | 2000-03-02 | Implex Hear Tech Ag | Charger arrangement for rechargeable Ni Cd, Ni-metal hydride, or Lithium batteries in implant, has current source which provides high initial current |
US6212431B1 (en) | 1998-09-08 | 2001-04-03 | Advanced Bionics Corporation | Power transfer circuit for implanted devices |
US7142925B1 (en) | 1998-09-16 | 2006-11-28 | Axon Engineering, Inc. | Combined stimulation of ventral and dorsal sacral roots for control of bladder function |
ATE328548T1 (en) | 1998-10-06 | 2006-06-15 | Bio Control Medical Ltd | CONTROL OF URGENT INCONTINENCE |
IL127481A (en) | 1998-10-06 | 2004-05-12 | Bio Control Medical Ltd | Incontinence treatment device |
US6275737B1 (en) | 1998-10-14 | 2001-08-14 | Advanced Bionics Corporation | Transcutaneous transmission pouch |
US5948006A (en) | 1998-10-14 | 1999-09-07 | Advanced Bionics Corporation | Transcutaneous transmission patch |
US7076307B2 (en) | 2002-05-09 | 2006-07-11 | Boveja Birinder R | Method and system for modulating the vagus nerve (10th cranial nerve) with electrical pulses using implanted and external components, to provide therapy neurological and neuropsychiatric disorders |
US20030212440A1 (en) | 2002-05-09 | 2003-11-13 | Boveja Birinder R. | Method and system for modulating the vagus nerve (10th cranial nerve) using modulated electrical pulses with an inductively coupled stimulation system |
AU6465399A (en) | 1998-10-30 | 2000-05-22 | Aalborg Universitet | A method to control an overactive bladder |
US5949632A (en) | 1998-12-01 | 1999-09-07 | Exonix Corporation | Power supply having means for extending the operating time of an implantable medical device |
US7555346B1 (en) | 1999-01-07 | 2009-06-30 | Boston Scientific Neuromodulation Corporation | Implantable pulse generator having current steering means |
US6052624A (en) | 1999-01-07 | 2000-04-18 | Advanced Bionics Corporation | Directional programming for implantable electrode arrays |
US6393325B1 (en) | 1999-01-07 | 2002-05-21 | Advanced Bionics Corporation | Directional programming for implantable electrode arrays |
US6321118B1 (en) | 1999-01-28 | 2001-11-20 | Advanced Bionics Corporation | Method and apparatus for power link detection with implantable medical devices |
AU772100B2 (en) | 1999-02-08 | 2004-04-08 | Cochlear Limited | Offset coils for radio frequency transcutaneous links |
US6172556B1 (en) | 1999-03-04 | 2001-01-09 | Intersil Corporation, Inc. | Feedback-controlled low voltage current sink/source |
US7131996B2 (en) | 1999-03-18 | 2006-11-07 | Helmut Wasserman | Artificial urinary diversion device |
AU4020300A (en) | 1999-03-24 | 2000-10-09 | Advanced Bionics, Inc. | Method and apparatus of a strong metal-ceramic braze bond |
WO2000056393A1 (en) | 1999-03-24 | 2000-09-28 | Second Sight, Llc | Retinal color prosthesis for color sight restoration |
US6181105B1 (en) | 1999-04-26 | 2001-01-30 | Exonix Corporation | Self contained transportable power source maintenance and charge |
US6166518A (en) | 1999-04-26 | 2000-12-26 | Exonix Corporation | Implantable power management system |
US6055456A (en) | 1999-04-29 | 2000-04-25 | Medtronic, Inc. | Single and multi-polar implantable lead for sacral nerve electrical stimulation |
US6212430B1 (en) | 1999-05-03 | 2001-04-03 | Abiomed, Inc. | Electromagnetic field source with detection of position of secondary coil in relation to multiple primary coils |
US6505075B1 (en) | 1999-05-29 | 2003-01-07 | Richard L. Weiner | Peripheral nerve stimulation method |
US7177690B2 (en) | 1999-07-27 | 2007-02-13 | Advanced Bionics Corporation | Implantable system having rechargeable battery indicator |
US6516227B1 (en) | 1999-07-27 | 2003-02-04 | Advanced Bionics Corporation | Rechargeable spinal cord stimulator system |
US6553263B1 (en) | 1999-07-30 | 2003-04-22 | Advanced Bionics Corporation | Implantable pulse generators using rechargeable zero-volt technology lithium-ion batteries |
US7295878B1 (en) | 1999-07-30 | 2007-11-13 | Advanced Bionics Corporation | Implantable devices using rechargeable zero-volt technology lithium-ion batteries |
US7047082B1 (en) | 1999-09-16 | 2006-05-16 | Micronet Medical, Inc. | Neurostimulating lead |
US6654642B2 (en) | 1999-09-29 | 2003-11-25 | Medtronic, Inc. | Patient interactive neurostimulation system and method |
US6381496B1 (en) | 1999-10-01 | 2002-04-30 | Advanced Bionics Corporation | Parameter context switching for an implanted device |
US6442434B1 (en) | 1999-10-19 | 2002-08-27 | Abiomed, Inc. | Methods and apparatus for providing a sufficiently stable power to a load in an energy transfer system |
US6466817B1 (en) | 1999-11-24 | 2002-10-15 | Nuvasive, Inc. | Nerve proximity and status detection system and method |
US7470236B1 (en) | 1999-11-24 | 2008-12-30 | Nuvasive, Inc. | Electromyography system |
US6438423B1 (en) | 2000-01-20 | 2002-08-20 | Electrocore Technique, Llc | Method of treating complex regional pain syndromes by electrical stimulation of the sympathetic nerve chain |
US6473652B1 (en) | 2000-03-22 | 2002-10-29 | Nac Technologies Inc. | Method and apparatus for locating implanted receiver and feedback regulation between subcutaneous and external coils |
US6662051B1 (en) | 2000-03-31 | 2003-12-09 | Stephen A. Eraker | Programmable pain reduction device |
CA2406158A1 (en) | 2000-04-20 | 2001-11-01 | Cochlear Limited | Transcutaneous power optimization circuit for cochlear implant |
US6453198B1 (en) | 2000-04-28 | 2002-09-17 | Medtronic, Inc. | Power management for an implantable medical device |
US7167756B1 (en) | 2000-04-28 | 2007-01-23 | Medtronic, Inc. | Battery recharge management for an implantable medical device |
US6327504B1 (en) | 2000-05-10 | 2001-12-04 | Thoratec Corporation | Transcutaneous energy transfer with circuitry arranged to avoid overheating |
US20020055688A1 (en) | 2000-05-18 | 2002-05-09 | Jefferson Jacob Katims | Nervous tissue stimulation device and method |
US6505077B1 (en) | 2000-06-19 | 2003-01-07 | Medtronic, Inc. | Implantable medical device with external recharging coil electrical connection |
US7305268B2 (en) | 2000-07-13 | 2007-12-04 | Northstar Neurscience, Inc. | Systems and methods for automatically optimizing stimulus parameters and electrode configurations for neuro-stimulators |
ES2318238T3 (en) | 2000-07-26 | 2009-05-01 | Boston Scientific Neuromodulation Corporation | STIMULATION SYSTEM |
IT1316598B1 (en) | 2000-08-07 | 2003-04-24 | Caen Microelettronica E Sistem | TEXTILE MANUFACTURE WITH ILLUMINATED FIBERS, ITEM OF CLOTHING OBTAINED AND PRODUCTION METHOD OF THE MANUFACTURE. |
US6510347B2 (en) | 2000-08-17 | 2003-01-21 | William N. Borkan | Spinal cord stimulation leads |
US7054689B1 (en) | 2000-08-18 | 2006-05-30 | Advanced Bionics Corporation | Fully implantable neurostimulator for autonomic nerve fiber stimulation as a therapy for urinary and bowel dysfunction |
DE10041728A1 (en) | 2000-08-25 | 2002-03-21 | Implex Hear Tech Ag | Implantable medicinal device with hermetically sealed housing has storage device accommodated directly within hermetically sealed housing without housing of its own |
DE10041727C2 (en) | 2000-08-25 | 2003-04-10 | Cochlear Ltd | Implantable hermetically sealed housing for an implantable medical device |
US6745077B1 (en) | 2000-10-11 | 2004-06-01 | Advanced Bionics Corporation | Electronic impedance transformer for inductively-coupled load stabilization |
US6842647B1 (en) | 2000-10-20 | 2005-01-11 | Advanced Bionics Corporation | Implantable neural stimulator system including remote control unit for use therewith |
US6542846B1 (en) | 2000-11-09 | 2003-04-01 | Koninklijke Philips Electronics N.V. | Thermal management system for a portable ultrasound imaging device |
US6971393B1 (en) | 2000-11-15 | 2005-12-06 | George Mamo | Minimally invasive method for implanting a sacral stimulation lead |
US6847849B2 (en) | 2000-11-15 | 2005-01-25 | Medtronic, Inc. | Minimally invasive apparatus for implanting a sacral stimulation lead |
US6600954B2 (en) | 2001-01-25 | 2003-07-29 | Biocontrol Medical Bcm Ltd. | Method and apparatus for selective control of nerve fibers |
US6975906B2 (en) | 2001-02-08 | 2005-12-13 | Wilson Greatbatch Ltd. | One piece header assembly over molded to an implantable medical device |
US6609945B2 (en) | 2001-02-08 | 2003-08-26 | Plexus, Inc. | Radio-controlled toy blimp with infrared beam weapons for staging a gun battle |
US6901287B2 (en) | 2001-02-09 | 2005-05-31 | Medtronic, Inc. | Implantable therapy delivery element adjustable anchor |
US6708065B2 (en) | 2001-03-02 | 2004-03-16 | Cardiac Pacemakers, Inc. | Antenna for an implantable medical device |
US6907293B2 (en) | 2001-03-30 | 2005-06-14 | Case Western Reserve University | Systems and methods for selectively stimulating components in, on, or near the pudendal nerve or its branches to achieve selective physiologic responses |
US6584355B2 (en) | 2001-04-10 | 2003-06-24 | Cardiac Pacemakers, Inc. | System and method for measuring battery current |
US8145324B1 (en) | 2001-04-13 | 2012-03-27 | Greatbatch Ltd. | Implantable lead bandstop filter employing an inductive coil with parasitic capacitance to enhance MRI compatibility of active medical devices |
US20070088416A1 (en) | 2001-04-13 | 2007-04-19 | Surgi-Vision, Inc. | Mri compatible medical leads |
US6892098B2 (en) | 2001-04-26 | 2005-05-10 | Biocontrol Medical Ltd. | Nerve stimulation for treating spasticity, tremor, muscle weakness, and other motor disorders |
KR100606307B1 (en) | 2001-05-23 | 2006-07-28 | 안태영 | Apparatus for contactless power transfer for medical implant |
JP4295086B2 (en) | 2001-07-11 | 2009-07-15 | ヌバシブ, インコーポレイテッド | System and method for determining nerve proximity, nerve orientation, and pathology during surgery |
US6456256B1 (en) | 2001-08-03 | 2002-09-24 | Cardiac Pacemakers, Inc. | Circumferential antenna for an implantable medical device |
US7151914B2 (en) | 2001-08-21 | 2006-12-19 | Medtronic, Inc. | Transmitter system for wireless communication with implanted devices |
US7734355B2 (en) | 2001-08-31 | 2010-06-08 | Bio Control Medical (B.C.M.) Ltd. | Treatment of disorders by unidirectional nerve stimulation |
US6999819B2 (en) | 2001-08-31 | 2006-02-14 | Medtronic, Inc. | Implantable medical electrical stimulation lead fixation method and apparatus |
EP2481338A3 (en) | 2001-09-25 | 2012-09-05 | Nuvasive, Inc. | System for performing surgical procedures and assessments |
US7187978B2 (en) | 2001-11-01 | 2007-03-06 | Medtronic, Inc. | Method and apparatus for programming an implantable medical device |
US6894456B2 (en) | 2001-11-07 | 2005-05-17 | Quallion Llc | Implantable medical power module |
US6721603B2 (en) | 2002-01-25 | 2004-04-13 | Cyberonics, Inc. | Nerve stimulation as a treatment for pain |
US7317948B1 (en) | 2002-02-12 | 2008-01-08 | Boston Scientific Scimed, Inc. | Neural stimulation system providing auto adjustment of stimulus output as a function of sensed impedance |
US20080077192A1 (en) | 2002-05-03 | 2008-03-27 | Afferent Corporation | System and method for neuro-stimulation |
JP3731881B2 (en) | 2002-05-23 | 2006-01-05 | 有限会社ティーエム | Non-invasive charging system for artificial organs, power storage device used in this system, and power supply device |
US7860570B2 (en) | 2002-06-20 | 2010-12-28 | Boston Scientific Neuromodulation Corporation | Implantable microstimulators and methods for unidirectional propagation of action potentials |
US7582058B1 (en) | 2002-06-26 | 2009-09-01 | Nuvasive, Inc. | Surgical access system and related methods |
CA2762938C (en) | 2002-06-28 | 2015-05-05 | Boston Scientific Neuromodulation Corporation | Microstimulator having self-contained power source and bi-directional telemetry system |
US8386048B2 (en) | 2002-06-28 | 2013-02-26 | Boston Scientific Neuromodulation Corporation | Systems and methods for communicating with or providing power to an implantable stimulator |
AU2002951217A0 (en) | 2002-09-04 | 2002-09-19 | Cochlear Limited | Method and apparatus for measurement of transmitter/receiver separation |
US7328068B2 (en) | 2003-03-31 | 2008-02-05 | Medtronic, Inc. | Method, system and device for treating disorders of the pelvic floor by means of electrical stimulation of the pudendal and associated nerves, and the optional delivery of drugs in association therewith |
US7369894B2 (en) | 2002-09-06 | 2008-05-06 | Medtronic, Inc. | Method, system and device for treating disorders of the pelvic floor by electrical stimulation of the sacral and/or pudendal nerves |
US20040055610A1 (en) | 2002-09-25 | 2004-03-25 | Peter Forsell | Detection of implanted wireless energy receiving device |
AU2002951739A0 (en) | 2002-09-30 | 2002-10-17 | Cochlear Limited | Feedthrough with multiple conductive pathways extending therethrough |
US7127298B1 (en) | 2002-10-18 | 2006-10-24 | Advanced Bionics Corporation | Switched-matrix output for multi-channel implantable stimulator |
AU2003285078A1 (en) | 2002-10-31 | 2004-06-07 | Medtronic, Inc. | Distributed system for neurostimulation therapy programming |
US7146219B2 (en) | 2002-10-31 | 2006-12-05 | Medtronic, Inc. | Applying filter information to identify combinations of electrodes |
US7933655B2 (en) | 2002-10-31 | 2011-04-26 | Medtronic, Inc. | Neurostimulation therapy manipulation |
US7167749B2 (en) | 2002-11-05 | 2007-01-23 | Wilson Greatbatch Technologies, Inc. | One piece header assembly for an implantable medical device |
US6990376B2 (en) | 2002-12-06 | 2006-01-24 | The Regents Of The University Of California | Methods and systems for selective control of bladder function |
US7952349B2 (en) | 2002-12-09 | 2011-05-31 | Ferro Solutions, Inc. | Apparatus and method utilizing magnetic field |
TR200202651A2 (en) | 2002-12-12 | 2004-07-21 | Met�N�Tulgar | the vücutádışındanádirekátedaviásinyaliátransferliáábeyinápil |
US6685638B1 (en) | 2002-12-23 | 2004-02-03 | Codman & Shurtleff, Inc. | Acoustic monitoring system |
US7742821B1 (en) | 2003-06-11 | 2010-06-22 | Boston Scientific Neutomodulation Corporation | Remote control for implantable medical device |
US7647116B2 (en) | 2003-03-13 | 2010-01-12 | Medtronic, Inc. | Context-sensitive collection of neurostimulation therapy data |
US9446229B2 (en) | 2003-04-08 | 2016-09-20 | Omar Omar-Pasha | Catheter |
US7463928B2 (en) | 2003-04-25 | 2008-12-09 | Medtronic, Inc. | Identifying combinations of electrodes for neurostimulation therapy |
US7444184B2 (en) | 2003-05-11 | 2008-10-28 | Neuro And Cardial Technologies, Llc | Method and system for providing therapy for bulimia/eating disorders by providing electrical pulses to vagus nerve(s) |
US20050187590A1 (en) | 2003-05-11 | 2005-08-25 | Boveja Birinder R. | Method and system for providing therapy for autism by providing electrical pulses to the vagus nerve(s) |
US7317947B2 (en) | 2003-05-16 | 2008-01-08 | Medtronic, Inc. | Headset recharger for cranially implantable medical devices |
US20040267137A1 (en) | 2003-06-27 | 2004-12-30 | Michael Peszynski | Apparatus and method for IC-based ultrasound transducer temperature sensing |
US20060149345A1 (en) | 2003-09-12 | 2006-07-06 | Ndi Medical, Llc | Neuromodulation stimulation for the restoration of sexual function |
US7617002B2 (en) | 2003-09-15 | 2009-11-10 | Medtronic, Inc. | Selection of neurostimulator parameter configurations using decision trees |
US7286880B2 (en) | 2003-10-02 | 2007-10-23 | Medtronic, Inc. | System and method for transcutaneous energy transfer achieving high efficiency |
US7515967B2 (en) | 2003-10-02 | 2009-04-07 | Medtronic, Inc. | Ambulatory energy transfer system for an implantable medical device and method therefore |
US7286881B2 (en) | 2003-10-02 | 2007-10-23 | Medtronic, Inc. | External power source having an adjustable magnetic core and method of use |
US8265770B2 (en) | 2003-10-02 | 2012-09-11 | Medtronic, Inc. | Driver circuitry switchable between energy transfer and telemetry for an implantable medical device |
US8140168B2 (en) | 2003-10-02 | 2012-03-20 | Medtronic, Inc. | External power source for an implantable medical device having an adjustable carrier frequency and system and method related therefore |
US7225032B2 (en) | 2003-10-02 | 2007-05-29 | Medtronic Inc. | External power source, charger and system for an implantable medical device having thermal characteristics and method therefore |
US20050075696A1 (en) | 2003-10-02 | 2005-04-07 | Medtronic, Inc. | Inductively rechargeable external energy source, charger, system and method for a transcutaneous inductive charger for an implantable medical device |
US6989200B2 (en) | 2003-10-30 | 2006-01-24 | Alfred E. Mann Foundation For Scientific Research | Ceramic to noble metal braze and method of manufacture |
US20080161874A1 (en) * | 2004-02-12 | 2008-07-03 | Ndi Medical, Inc. | Systems and methods for a trial stage and/or long-term treatment of disorders of the body using neurostimulation |
US7120499B2 (en) | 2004-02-12 | 2006-10-10 | Ndi Medical, Llc | Portable percutaneous assemblies, systems and methods for providing highly selective functional or therapeutic neuromuscular stimulation |
US8086318B2 (en) | 2004-02-12 | 2011-12-27 | Ndi Medical, Llc | Portable assemblies, systems, and methods for providing functional or therapeutic neurostimulation |
US8467875B2 (en) | 2004-02-12 | 2013-06-18 | Medtronic, Inc. | Stimulation of dorsal genital nerves to treat urologic dysfunctions |
ATE520440T1 (en) | 2004-02-12 | 2011-09-15 | Ndi Medical Llc | WEARABLE ARRANGEMENTS AND SYSTEMS FOR FUNCTIONAL OR THERAPEUTIC NEUROMUSCULAR STIMULATION |
US20080132969A1 (en) | 2004-02-12 | 2008-06-05 | Ndi Medical, Inc. | Systems and methods for bilateral stimulation of left and right branches of the dorsal genital nerves to treat urologic dysfunctions |
WO2005082453A1 (en) | 2004-02-25 | 2005-09-09 | Advanced Neuromodulation Systems, Inc. | System and method for neurological stimulation of peripheral nerves to treat low back pain |
US7738963B2 (en) | 2004-03-04 | 2010-06-15 | Advanced Neuromodulation Systems, Inc. | System and method for programming an implantable pulse generator |
US7844343B2 (en) | 2004-03-30 | 2010-11-30 | Medtronic, Inc. | MRI-safe implantable medical device |
US7212110B1 (en) | 2004-04-19 | 2007-05-01 | Advanced Neuromodulation Systems, Inc. | Implantable device and system and method for wireless communication |
US7532936B2 (en) | 2004-04-20 | 2009-05-12 | Advanced Neuromodulation Systems, Inc. | Programmable switching device for implantable device |
US7245972B2 (en) | 2004-04-29 | 2007-07-17 | Alfred E. Mann Foundation For Scientific Research | Electrical treatment to treat shoulder subluxation |
US7359751B1 (en) | 2004-05-05 | 2008-04-15 | Advanced Neuromodulation Systems, Inc. | Clinician programmer for use with trial stimulator |
US7225028B2 (en) | 2004-05-28 | 2007-05-29 | Advanced Bionics Corporation | Dual cochlear/vestibular stimulator with control signals derived from motion and speech signals |
US7539538B2 (en) | 2004-05-28 | 2009-05-26 | Boston Science Neuromodulation Corporation | Low power loss current digital-to-analog converter used in an implantable pulse generator |
US7450991B2 (en) | 2004-05-28 | 2008-11-11 | Advanced Neuromodulation Systems, Inc. | Systems and methods used to reserve a constant battery capacity |
WO2005123185A1 (en) | 2004-06-10 | 2005-12-29 | Ndi Medical, Llc | Implantable system for processing myoelectric signals |
US7761167B2 (en) | 2004-06-10 | 2010-07-20 | Medtronic Urinary Solutions, Inc. | Systems and methods for clinician control of stimulation systems |
US9205255B2 (en) | 2004-06-10 | 2015-12-08 | Medtronic Urinary Solutions, Inc. | Implantable pulse generator systems and methods for providing functional and/or therapeutic stimulation of muscles and/or nerves and/or central nervous system tissue |
US9308382B2 (en) | 2004-06-10 | 2016-04-12 | Medtronic Urinary Solutions, Inc. | Implantable pulse generator systems and methods for providing functional and/or therapeutic stimulation of muscles and/or nerves and/or central nervous system tissue |
KR100624294B1 (en) * | 2004-06-16 | 2006-09-19 | 주식회사 대우일렉트로닉스 | Method for converting broadcasting channel of television |
DE602005020965D1 (en) | 2004-07-20 | 2010-06-10 | Medtronic Inc | LOCALIZATION OF AN IMPLANT OBJECT BASED ON AN EXTERNAL ANTENNA CHARGE |
US7771838B1 (en) | 2004-10-12 | 2010-08-10 | Boston Scientific Neuromodulation Corporation | Hermetically bonding ceramic and titanium with a Ti-Pd braze interface |
US7578819B2 (en) | 2005-05-16 | 2009-08-25 | Baxano, Inc. | Spinal access and neural localization |
US8417352B2 (en) * | 2004-10-19 | 2013-04-09 | Meagan Medical, Inc. | System and method for stimulating sensory nerves |
US8768452B2 (en) | 2005-02-23 | 2014-07-01 | Medtronic, Inc. | Implantable neurostimulator supporting trial and chronic modes |
US8774912B2 (en) | 2005-02-23 | 2014-07-08 | Medtronic, Inc. | Implantable neurostimulator supporting trial and chronic modes |
US7580752B2 (en) | 2005-02-23 | 2009-08-25 | Medtronic, Inc. | Implantable medical device providing adaptive neurostimulation therapy for incontinence |
US20060200205A1 (en) | 2005-03-01 | 2006-09-07 | Haller Matthew I | Systems and methods for treating a patient with multiple stimulation therapies |
US7979119B2 (en) | 2005-04-26 | 2011-07-12 | Boston Scientific Neuromodulation Corporation | Display graphics for use in stimulation therapies |
US7406351B2 (en) | 2005-04-28 | 2008-07-29 | Medtronic, Inc. | Activity sensing for stimulator control |
US7774069B2 (en) | 2005-04-29 | 2010-08-10 | Medtronic, Inc. | Alignment indication for transcutaneous energy transfer |
US8244360B2 (en) | 2005-06-09 | 2012-08-14 | Medtronic, Inc. | Regional therapies for treatment of pain |
KR100792311B1 (en) | 2005-07-30 | 2008-01-07 | 엘에스전선 주식회사 | Rechargeable power supply, rechargeable device, battery device, contactless recharger system and method for charging rechargeable battery cell |
US8175717B2 (en) | 2005-09-06 | 2012-05-08 | Boston Scientific Neuromodulation Corporation | Ultracapacitor powered implantable pulse generator with dedicated power supply |
US7640059B2 (en) | 2005-09-08 | 2009-12-29 | Medtronic, Inc. | External presentation of electrical stimulation parameters |
US7650192B2 (en) | 2005-12-02 | 2010-01-19 | Medtronic, Inc. | Passive charge of implantable medical device utilizing external power source and method |
US7444181B2 (en) | 2005-12-14 | 2008-10-28 | Boston Scientific Neuromodulation Corporation | Techniques for sensing and adjusting a compliance voltage in an implantable stimulator device |
US7720547B2 (en) | 2006-01-04 | 2010-05-18 | Kenergy, Inc. | Extracorporeal power supply with a wireless feedback system for an implanted medical device |
US7809443B2 (en) | 2006-01-31 | 2010-10-05 | Medtronic, Inc. | Electrical stimulation to alleviate chronic pelvic pain |
US8019423B2 (en) | 2006-02-17 | 2011-09-13 | Marc Possover | Laparoscopic implantation of neurostimulators |
US7747330B2 (en) | 2006-03-09 | 2010-06-29 | Medtronic, Inc. | Global parameter adjustment for multiple stimulation programs |
US8447402B1 (en) | 2006-03-31 | 2013-05-21 | Alfred E. Mann Foundation For Scientific Research | Zirconia to platinum assembly using a titanium connector |
US7715920B2 (en) | 2006-04-28 | 2010-05-11 | Medtronic, Inc. | Tree-based electrical stimulator programming |
US8219202B2 (en) | 2006-04-28 | 2012-07-10 | Medtronic, Inc. | Electrical stimulation of ilioinguinal nerve to alleviate chronic pelvic pain |
US8892214B2 (en) | 2006-04-28 | 2014-11-18 | Medtronic, Inc. | Multi-electrode peripheral nerve evaluation lead and related system and method of use |
US7738965B2 (en) | 2006-04-28 | 2010-06-15 | Medtronic, Inc. | Holster for charging pectorally implanted medical devices |
US7761166B2 (en) | 2006-04-28 | 2010-07-20 | Medtronic, Inc. | Electrical stimulation of iliohypogastric nerve to alleviate chronic pelvic pain |
US20070265675A1 (en) | 2006-05-09 | 2007-11-15 | Ams Research Corporation | Testing Efficacy of Therapeutic Mechanical or Electrical Nerve or Muscle Stimulation |
KR101379640B1 (en) | 2006-06-05 | 2014-04-11 | 에이엠에스 리서치 코포레이션 | Electrical muscle stimulation to treat fecal incontinence and/or pelvic prolapse |
US20070282376A1 (en) | 2006-06-06 | 2007-12-06 | Shuros Allan C | Method and apparatus for neural stimulation via the lymphatic system |
US8116862B2 (en) | 2006-06-08 | 2012-02-14 | Greatbatch Ltd. | Tank filters placed in series with the lead wires or circuits of active medical devices to enhance MRI compatibility |
WO2008021524A2 (en) | 2006-08-18 | 2008-02-21 | Second Sight Medical Products, Inc. | Package for an implantable neural stimulation device |
US7979126B2 (en) | 2006-10-18 | 2011-07-12 | Boston Scientific Neuromodulation Corporation | Orientation-independent implantable pulse generator |
US20100076534A1 (en) | 2006-10-25 | 2010-03-25 | William Alan Mock | Malleable needle having a plurality of electrodes for facilitating implantation of stimulation lead and method of implanting an electrical stimulation lead |
US9643004B2 (en) | 2006-10-31 | 2017-05-09 | Medtronic, Inc. | Implantable medical elongated member with adhesive elements |
US9713706B2 (en) | 2006-10-31 | 2017-07-25 | Medtronic, Inc. | Implantable medical elongated member including intermediate fixation |
US20080103572A1 (en) | 2006-10-31 | 2008-05-01 | Medtronic, Inc. | Implantable medical lead with threaded fixation |
US9827415B2 (en) | 2006-11-09 | 2017-11-28 | Greatbatch Ltd. | Implantable lead having multi-planar spiral inductor filter |
CN200984399Y (en) * | 2006-12-14 | 2007-12-05 | 英业达股份有限公司 | Low-cycle electrotherapeutics device |
US9044592B2 (en) | 2007-01-29 | 2015-06-02 | Spinal Modulation, Inc. | Sutureless lead retention features |
US9615744B2 (en) | 2007-01-31 | 2017-04-11 | Medtronic, Inc. | Chopper-stabilized instrumentation amplifier for impedance measurement |
US7391257B1 (en) | 2007-01-31 | 2008-06-24 | Medtronic, Inc. | Chopper-stabilized instrumentation amplifier for impedance measurement |
US8549015B2 (en) | 2007-05-01 | 2013-10-01 | Giancarlo Barolat | Method and system for distinguishing nociceptive pain from neuropathic pain |
US7932696B2 (en) | 2007-05-14 | 2011-04-26 | Boston Scientific Neuromodulation Corporation | Charger alignment indicator with adjustable threshold |
US9427573B2 (en) | 2007-07-10 | 2016-08-30 | Astora Women's Health, Llc | Deployable electrode lead anchor |
CA2733081C (en) | 2007-08-06 | 2015-12-15 | Great Lakes Biosciences, Llc | Methods and apparatus for electrical stimulation of tissues using signals that minimize the effects of tissue impedance |
US20090071686A1 (en) | 2007-09-13 | 2009-03-19 | Medtronic, Inc. | Medical electrical lead |
US10307597B2 (en) * | 2007-10-11 | 2019-06-04 | Peter Forsell | Method for controlling flow of urine in a patient's urethra, ureter, renal pelvis or bladder |
WO2009055203A1 (en) | 2007-10-26 | 2009-04-30 | Medtronic, Inc. | Method and apparatus for dynamic adjustment of recharge parameters |
US9199075B1 (en) | 2008-02-07 | 2015-12-01 | Respicardia, Inc. | Transvascular medical lead |
US8332040B1 (en) | 2008-03-10 | 2012-12-11 | Advanced Neuromodulation Systems, Inc. | External charging device for charging an implantable medical device and methods of regulating duty of cycle of an external charging device |
US9233253B2 (en) | 2012-01-16 | 2016-01-12 | Greatbatch Ltd. | EMI filtered co-connected hermetic feedthrough, feedthrough capacitor and leadwire assembly for an active implantable medical device |
EP2269200B1 (en) | 2008-03-20 | 2014-09-24 | Greatbatch Ltd. | Shielded three-terminal flat-through emi/energy dissipating filter |
US8019443B2 (en) | 2008-04-01 | 2011-09-13 | Boston Scientific Neuromodulation Corporation | Anchoring units for leads of implantable electric stimulation systems and methods of making and using |
JP5587864B2 (en) | 2008-04-11 | 2014-09-10 | バル・シール・エンジニアリング・インコーポレイテッド | Connector cartridge laminate for power transfer |
US9238135B2 (en) | 2008-04-30 | 2016-01-19 | Medtronic, Inc. | Flagging of electrodes of an implantable medical device, controller, system and method therefore |
JP2011518629A (en) | 2008-04-30 | 2011-06-30 | ミルックス・ホールディング・エスエイ | Brain stimulation |
US8314594B2 (en) | 2008-04-30 | 2012-11-20 | Medtronic, Inc. | Capacity fade adjusted charge level or recharge interval of a rechargeable power source of an implantable medical device, system and method |
US8103360B2 (en) | 2008-05-09 | 2012-01-24 | Foster Arthur J | Medical lead coil conductor with spacer element |
US7890182B2 (en) | 2008-05-15 | 2011-02-15 | Boston Scientific Neuromodulation Corporation | Current steering for an implantable stimulator device involving fractionalized stimulation pulses |
US7957818B2 (en) | 2008-06-26 | 2011-06-07 | Greatbatch Ltd. | Stimulation lead design and method of manufacture |
US8055337B2 (en) | 2008-07-24 | 2011-11-08 | Boston Scientific Neuromodulation Corporation | System and method for maintaining a distribution of currents in an electrode array using independent voltage sources |
WO2010035177A1 (en) * | 2008-09-25 | 2010-04-01 | Koninklijke Philips Electronics N.V. | Apparatus with wireless communication module |
US9987493B2 (en) | 2008-10-28 | 2018-06-05 | Medtronic, Inc. | Medical devices and methods for delivery of current-based electrical stimulation therapy |
US8219196B2 (en) | 2008-10-31 | 2012-07-10 | Medtronic, Inc. | Determination of stimulation output capabilities throughout power source voltage range |
US8311639B2 (en) | 2009-07-08 | 2012-11-13 | Nevro Corporation | Systems and methods for adjusting electrical therapy based on impedance changes |
US8255057B2 (en) | 2009-01-29 | 2012-08-28 | Nevro Corporation | Systems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions |
US8538530B1 (en) | 2008-11-19 | 2013-09-17 | Advanced Bionics | Hermetically sealed feedthrough case |
US8712540B2 (en) | 2008-11-26 | 2014-04-29 | Medtronic, Inc. | Patient programmer with automated MRI compatibility verification for active implantable medical device |
CN201353233Y (en) * | 2008-12-30 | 2009-12-02 | 胡俊伏 | Multifunctional therapeutic apparatus |
EP2403589B1 (en) | 2009-02-10 | 2014-01-22 | Nevro Corporation | Systems for delivering neural therapy correlated with patient status |
JP5350016B2 (en) | 2009-02-27 | 2013-11-27 | 国立大学法人 東京医科歯科大学 | Jaw movement measurement system |
US9561366B2 (en) | 2009-03-27 | 2017-02-07 | Medtronic, Inc. | Conditional electrical stimulation |
DE202010018338U1 (en) * | 2009-04-22 | 2015-10-12 | Nevro Corporation | Spinal cord modulation system for the relief of chronic pain |
US9764147B2 (en) | 2009-04-24 | 2017-09-19 | Medtronic, Inc. | Charge-based stimulation intensity programming with pulse amplitude and width adjusted according to a function |
WO2010123704A2 (en) | 2009-04-24 | 2010-10-28 | Medtronic, Inc. | Incontinence therapy |
US8214042B2 (en) | 2009-05-26 | 2012-07-03 | Boston Scientific Neuromodulation Corporation | Techniques for controlling charging of batteries in an external charger and an implantable medical device |
US8498710B2 (en) | 2009-07-28 | 2013-07-30 | Nevro Corporation | Linked area parameter adjustment for spinal cord stimulation and associated systems and methods |
US9468755B2 (en) | 2009-09-30 | 2016-10-18 | Respicardia, Inc. | Medical lead with preformed bias |
WO2011046586A1 (en) | 2009-10-13 | 2011-04-21 | Incumed Llc | Neural stimulator with percutaneous connectivity |
US8571677B2 (en) | 2009-10-21 | 2013-10-29 | Medtronic, Inc. | Programming techniques for stimulation with utilization of case electrode |
US8577474B2 (en) | 2009-11-11 | 2013-11-05 | Boston Scientific Neuromodulation Corporation | Minimizing interference between charging and telemetry coils in an implantable medical device |
US8457756B2 (en) | 2009-11-11 | 2013-06-04 | Boston Scientific Neuromodulation Corporation | Using the case of an implantable medical device to broaden communication bandwidth |
EP3636314B1 (en) | 2009-12-23 | 2021-09-08 | Setpoint Medical Corporation | Neural stimulation devices and systems for treatment of chronic inflammation |
US20110179637A1 (en) | 2010-01-24 | 2011-07-28 | Kevin Wilmot Eberman | Slurry coating method for making batteries |
US9314616B2 (en) | 2010-04-14 | 2016-04-19 | Medtronic, Inc. | Temporary implantable medical electrical leads |
US9901284B2 (en) | 2010-04-16 | 2018-02-27 | Medtronic, Inc. | Coordination of functional MRI scanning and electrical stimulation therapy |
US9020589B2 (en) | 2010-04-27 | 2015-04-28 | Medtronic, Inc. | Electrical stimulator with voltage mode emulation using regulated current |
JP5774683B2 (en) | 2010-05-11 | 2015-09-09 | カーディアック ペースメイカーズ, インコーポレイテッド | Implantable medical device with means to automatically recover from interrupted therapy |
WO2011156287A2 (en) | 2010-06-07 | 2011-12-15 | Medtronic, Inc. | Selective termination of stimulation to deliver post-stimulation therapeutic effect |
US8812128B2 (en) * | 2010-11-17 | 2014-08-19 | Boston Scientific Neuromodulation Corporation | Implantable neurostimulator-initiated status notification |
US9293741B1 (en) | 2010-12-29 | 2016-03-22 | Greatbatch Ltd. | Mechanical conditioning by bead blasting lithium iodine cell case |
US9168374B2 (en) | 2011-01-28 | 2015-10-27 | Medtronic, Inc. | Intra-burst pulse variation for stimulation therapy |
CN106902457B (en) * | 2011-01-28 | 2022-10-21 | 斯蒂维科技公司 | Neurostimulator system |
US9757558B2 (en) | 2011-03-01 | 2017-09-12 | Greatbatch Ltd. | RF filter for an active medical device (AMD) for handling high RF power induced in an associated implanted lead from an external RF field |
US9931514B2 (en) | 2013-06-30 | 2018-04-03 | Greatbatch Ltd. | Low impedance oxide resistant grounded capacitor for an AIMD |
US8543223B2 (en) | 2011-03-11 | 2013-09-24 | Greatbach Ltd. | Implantable lead with braided conductors |
US9166321B2 (en) | 2011-03-22 | 2015-10-20 | Greatbatch Ltd. | Thin profile stacked layer contact |
US9931513B2 (en) | 2011-03-29 | 2018-04-03 | Nuvectra Corporation | Feed-through connector assembly for implantable pulse generator and method of use |
US8996117B2 (en) | 2011-04-07 | 2015-03-31 | Greatbatch, Ltd. | Arbitrary waveform generator and neural stimulation application with scalable waveform feature |
US8738141B2 (en) | 2011-04-07 | 2014-05-27 | Greatbatch, Ltd. | Contact assembly for implantable pulse generator and method of use |
US9656076B2 (en) | 2011-04-07 | 2017-05-23 | Nuvectra Corporation | Arbitrary waveform generator and neural stimulation application with scalable waveform feature and charge balancing |
US9623257B2 (en) | 2011-04-18 | 2017-04-18 | Medtronic, Inc. | Recharge tuning techniques for an implantable device |
US9265958B2 (en) | 2011-04-29 | 2016-02-23 | Cyberonics, Inc. | Implantable medical device antenna |
US10448889B2 (en) | 2011-04-29 | 2019-10-22 | Medtronic, Inc. | Determining nerve location relative to electrodes |
US8515545B2 (en) | 2011-04-29 | 2013-08-20 | Greatbatch Ltd. | Current steering neurostimulator device with unidirectional current sources |
US9789307B2 (en) | 2011-04-29 | 2017-10-17 | Medtronic, Inc. | Dual prophylactic and abortive electrical stimulation |
US9089712B2 (en) | 2011-04-29 | 2015-07-28 | Cyberonics, Inc. | Implantable medical device without antenna feedthrough |
US9240630B2 (en) | 2011-04-29 | 2016-01-19 | Cyberonics, Inc. | Antenna shield for an implantable medical device |
US9259582B2 (en) | 2011-04-29 | 2016-02-16 | Cyberonics, Inc. | Slot antenna for an implantable device |
US9592389B2 (en) | 2011-05-27 | 2017-03-14 | Boston Scientific Neuromodulation Corporation | Visualization of relevant stimulation leadwire electrodes relative to selected stimulation information |
US9144680B2 (en) | 2011-05-31 | 2015-09-29 | Greatbatch Ltd. | System and method of establishing a protocol for providing electrical stimulation with a stimulation system to treat a patient |
US9375574B2 (en) | 2011-05-31 | 2016-06-28 | Nuvectra Corporation | System and method of providing computer assisted stimulation programming (CASP) |
US8954148B2 (en) | 2011-06-28 | 2015-02-10 | Greatbatch, Ltd. | Key fob controller for an implantable neurostimulator |
US20130197607A1 (en) * | 2011-06-28 | 2013-08-01 | Greatbatch Ltd. | Dual patient controllers |
US20130006330A1 (en) * | 2011-06-28 | 2013-01-03 | Greatbatch, Ltd. | Dual patient controllers |
US8571667B2 (en) | 2011-07-01 | 2013-10-29 | Greatbatch Ltd. | Active current control using the enclosure of an implanted pulse generator |
US9399135B2 (en) | 2011-07-12 | 2016-07-26 | Astora Women's Health, Llc | Electronic stimulator device pulse generator circuit |
US9675809B2 (en) | 2011-07-14 | 2017-06-13 | Cyberonics, Inc. | Circuit, system and method for far-field radiative powering of an implantable medical device |
US9492678B2 (en) | 2011-07-14 | 2016-11-15 | Cyberonics, Inc. | Far field radiative powering of implantable medical therapy delivery devices |
US8700175B2 (en) | 2011-07-19 | 2014-04-15 | Greatbatch Ltd. | Devices and methods for visually indicating the alignment of a transcutaneous energy transfer device over an implanted medical device |
US9393433B2 (en) | 2011-07-20 | 2016-07-19 | Boston Scientific Neuromodulation Corporation | Battery management for an implantable medical device |
US9925382B2 (en) | 2011-08-09 | 2018-03-27 | Boston Scientific Neuromodulation Corporation | Systems and methods for stimulation-related volume analysis, creation, and sharing |
US9517333B2 (en) | 2011-08-31 | 2016-12-13 | Nuvectra Corporation | Lead identification system |
AU2012332102B2 (en) | 2011-11-04 | 2017-05-04 | Nevro Corporation | Medical device communication and charding assemblies for use with implantable signal generators |
US9814884B2 (en) | 2011-11-04 | 2017-11-14 | Nevro Corp. | Systems and methods for detecting faults and/or adjusting electrical therapy based on impedance changes |
EP2788073B1 (en) | 2011-11-10 | 2018-03-21 | Medtronic Inc. | Introduction and anchoring tool for an implantable medical device element |
US10328253B2 (en) | 2011-11-30 | 2019-06-25 | Medtronic, Inc. | Medical electrical stimulation lead including expandable coiled fixation element |
US9889306B2 (en) | 2012-01-16 | 2018-02-13 | Greatbatch Ltd. | Hermetically sealed feedthrough with co-fired filled via and conductive insert for an active implantable medical device |
US9270134B2 (en) | 2012-01-27 | 2016-02-23 | Medtronic, Inc. | Adaptive rate recharging system |
US9981137B2 (en) | 2012-01-27 | 2018-05-29 | Nuvectra Corporation | Heat dispersion for implantable medical devices |
US9974108B2 (en) | 2012-02-06 | 2018-05-15 | Nuvectra Corporation | Paired communication between an implanted medical device and an external control device |
US9522282B2 (en) | 2012-03-29 | 2016-12-20 | Cyberonics, Inc. | Powering multiple implantable medical therapy delivery devices using far field radiative powering at multiple frequencies |
US10086191B2 (en) | 2012-04-19 | 2018-10-02 | Medtronic, Inc. | Medical leads having a distal body and an openly coiled filar |
US9653935B2 (en) | 2012-04-20 | 2017-05-16 | Medtronic, Inc. | Sensing temperature within medical devices |
US9436481B2 (en) | 2012-04-23 | 2016-09-06 | Medtronic, Inc. | Restoration of medical device programming |
EP2841150B1 (en) | 2012-04-26 | 2020-09-30 | Medtronic, Inc. | Trial stimulation systems |
US9878168B2 (en) | 2012-04-26 | 2018-01-30 | Medtronic, Inc. | Trial stimulation systems |
WO2013162709A1 (en) | 2012-04-26 | 2013-10-31 | Medtronic, Inc. | Trial stimulation systems |
US9149635B2 (en) | 2012-04-27 | 2015-10-06 | Medtronic, Inc. | Stimulation waveform generator for an implantable medical device |
US9358039B2 (en) | 2012-05-08 | 2016-06-07 | Greatbatch Ltd. | Transseptal needle apparatus |
US8706239B2 (en) | 2012-05-31 | 2014-04-22 | Pacesetter, Inc. | Systems and methods for controlling neurostimulation based on regional cardiac performance for use by implantable medical devices |
US10195419B2 (en) | 2012-06-13 | 2019-02-05 | Mainstay Medical Limited | Electrode leads for use with implantable neuromuscular electrical stimulator |
US9833614B1 (en) | 2012-06-22 | 2017-12-05 | Nevro Corp. | Autonomic nervous system control via high frequency spinal cord modulation, and associated systems and methods |
CA2870061A1 (en) | 2012-06-25 | 2014-01-03 | Boston Scientific Neuromodulation Corporation | Neurostimulation system for enabling magnetic field sensing with a shut-down hall sensor |
US9427571B2 (en) | 2012-06-29 | 2016-08-30 | Nuvectra Corporation | Dynamic coil for implantable stimulation leads |
US9089693B2 (en) | 2012-06-29 | 2015-07-28 | Greatbatch Ltd. | Lead positioning and finned fixation system |
JP2014033733A (en) * | 2012-08-07 | 2014-02-24 | Topcon Corp | Slit-lamp microscope |
AU2013308906B2 (en) | 2012-08-28 | 2016-07-21 | Boston Scientific Neuromodulation Corporation | Point-and-click programming for deep brain stimulation using real-time monopolar review trendlines |
US8761897B2 (en) | 2012-08-31 | 2014-06-24 | Greatbatch Ltd. | Method and system of graphical representation of lead connector block and implantable pulse generators on a clinician programmer |
US9375582B2 (en) | 2012-08-31 | 2016-06-28 | Nuvectra Corporation | Touch screen safety controls for clinician programmer |
US9259577B2 (en) | 2012-08-31 | 2016-02-16 | Greatbatch Ltd. | Method and system of quick neurostimulation electrode configuration and positioning |
US9471753B2 (en) | 2012-08-31 | 2016-10-18 | Nuvectra Corporation | Programming and virtual reality representation of stimulation parameter Groups |
US9507912B2 (en) | 2012-08-31 | 2016-11-29 | Nuvectra Corporation | Method and system of simulating a pulse generator on a clinician programmer |
US8903496B2 (en) | 2012-08-31 | 2014-12-02 | Greatbatch Ltd. | Clinician programming system and method |
US9767255B2 (en) | 2012-09-05 | 2017-09-19 | Nuvectra Corporation | Predefined input for clinician programmer data entry |
US9225190B2 (en) | 2012-09-07 | 2015-12-29 | Manufacturers And Traders Trust Company | Implant current controlled battery charging based on temperature |
US9209634B2 (en) | 2012-09-07 | 2015-12-08 | Greatbatch Ltd. | Method of improving battery recharge efficiency by statistical analysis |
US9884196B2 (en) * | 2012-10-10 | 2018-02-06 | Boston Scientific Neuromodulation Corporation | Neurostimulation programmer and method for directly assigning parameter values to electrodes |
WO2014087337A1 (en) | 2012-12-06 | 2014-06-12 | Bluewind Medical Ltd. | Delivery of implantable neurostimulators |
US9585642B2 (en) | 2012-12-07 | 2017-03-07 | Medtronic, Inc. | Minimally invasive implantable neurostimulation system |
US9308022B2 (en) | 2012-12-10 | 2016-04-12 | Nevro Corporation | Lead insertion devices and associated systems and methods |
WO2014093178A2 (en) | 2012-12-14 | 2014-06-19 | Boston Scientific Neuromodulation Corporation | Method for automation of therapy-based programming in a tissue stimulator user interface |
US9352148B2 (en) | 2013-02-27 | 2016-05-31 | Greatbatch Ltd. | Header block for an AIMD with an abandoned lead connector cavity |
US20140275968A1 (en) | 2013-03-13 | 2014-09-18 | Greatbatch Ltd. | Surrogate implanted medical device for energy dissipation of existing implanted leads during mri scans |
US9002447B2 (en) | 2013-03-14 | 2015-04-07 | Medtronic, Inc. | Implantable medical device having power supply for generating a regulated power supply |
US9472916B2 (en) | 2013-03-14 | 2016-10-18 | Medtronic, Inc. | Distal connector assemblies for medical lead extensions |
WO2014179685A1 (en) | 2013-05-03 | 2014-11-06 | Nevro Corporation | Molded headers for implantable signal generators, and associated systems and methods |
US9452294B2 (en) | 2013-05-16 | 2016-09-27 | Nuvectra Corporation | Automatic current balancing with lock control for a clinician programmer |
US9155889B2 (en) * | 2013-06-21 | 2015-10-13 | Boston Scientific Neuromodulation Corporation | Methods and apparatus for treating glioma |
US9265935B2 (en) | 2013-06-28 | 2016-02-23 | Nevro Corporation | Neurological stimulation lead anchors and associated systems and methods |
US20150018911A1 (en) | 2013-07-02 | 2015-01-15 | Greatbatch Ltd. | Apparatus, system, and method for minimized energy in peripheral field stimulation |
US9427592B2 (en) | 2013-08-28 | 2016-08-30 | Pacesetter, Inc. | Systems and methods for low energy wake-up and pairing for use with implantable medical devices |
US9068587B2 (en) | 2013-09-20 | 2015-06-30 | Greatbach Ltd. | Set screw apparatus |
US9205258B2 (en) | 2013-11-04 | 2015-12-08 | ElectroCore, LLC | Nerve stimulator system |
EP2870979B1 (en) | 2013-11-08 | 2021-01-06 | Nuvectra Corporation | Implantable medical lead for stimulation of multiple nerves |
US9502754B2 (en) | 2014-01-24 | 2016-11-22 | Medtronic, Inc. | Implantable medical devices having cofire ceramic modules and methods of fabricating the same |
US9364658B2 (en) | 2014-03-03 | 2016-06-14 | Boston Scientific Neuromodulation Corporation | Electrical stimulation leads with multiple anchoring units and methods of making and using |
US9457188B2 (en) | 2014-03-03 | 2016-10-04 | Medtronic, Inc. | Therapeutic window determination |
US9757555B2 (en) | 2014-04-24 | 2017-09-12 | Medtronic, Inc. | Pre-molded sub-assemblies for implantable medical leads |
US9981121B2 (en) | 2014-04-28 | 2018-05-29 | Medtronic, Inc. | Implantable medical devices, systems and components thereof |
US10092747B2 (en) | 2014-05-02 | 2018-10-09 | Nevro Corporation | MRI compatible medical devices |
WO2015175572A1 (en) | 2014-05-12 | 2015-11-19 | Micron Devices Llc | Remote rf power system with low profile transmitting antenna |
AU2015264561B2 (en) | 2014-05-20 | 2020-02-20 | Nevro Corporation | Implanted pulse generators with reduced power consumption via signal strength/duration characteristics, and associated systems and methods |
US9775984B2 (en) | 2014-08-01 | 2017-10-03 | Nuvectra Corporation | Apparatus with unencapsulated reinforcement |
US9924904B2 (en) | 2014-09-02 | 2018-03-27 | Medtronic, Inc. | Power-efficient chopper amplifier |
AU2015336218B2 (en) | 2014-10-22 | 2020-07-23 | Nevro Corp. | Systems and methods for extending the life of an implanted pulse generator battery |
US9597507B2 (en) | 2014-10-31 | 2017-03-21 | Medtronic, Inc. | Paired stimulation pulses based on sensed compound action potential |
US10095837B2 (en) | 2014-11-21 | 2018-10-09 | Medtronic, Inc. | Real-time phase detection of frequency band |
US9498628B2 (en) | 2014-11-21 | 2016-11-22 | Medtronic, Inc. | Electrode selection for electrical stimulation therapy |
US9907955B2 (en) | 2014-11-25 | 2018-03-06 | Medtronic Bakken Research Center B.V. | Disturbing magnetic resonance imaging (MRI) images using implantable medical device |
US10183162B2 (en) | 2015-01-02 | 2019-01-22 | Greatbatch Ltd. | Coiled, closed-loop RF current attenuator configured to be placed about an implantable lead conductor |
EP3242712B1 (en) | 2015-01-09 | 2019-04-10 | Axonics Modulation Technologies, Inc. | Patient remote and associated methods of use with a nerve stimulation system |
US10277055B2 (en) | 2015-02-26 | 2019-04-30 | Greatbatch Ltd. | Battery wireless charging system |
US10226636B2 (en) | 2015-04-24 | 2019-03-12 | Medtronic, Inc. | Managing recharge power for implantable medical devices |
US10076667B2 (en) | 2015-06-09 | 2018-09-18 | Nuvectra Corporation | System and method of performing computer assisted stimulation programming (CASP) with a non-zero starting value customized to a patient |
US10052490B2 (en) | 2015-06-09 | 2018-08-21 | Nuvectra Corporation | Systems, methods, and devices for performing electronically controlled test stimulation |
US9872988B2 (en) | 2015-06-09 | 2018-01-23 | Nuvectra Corporation | Systems, methods, and devices for evaluating lead placement based on patient physiological responses |
US9974949B2 (en) | 2015-10-16 | 2018-05-22 | Cyberonics, Inc. | MRI-safe implantable lead assembly |
ES2904702T3 (en) | 2015-12-31 | 2022-04-05 | Nevro Corp | Controller for nerve stimulation circuit and associated systems and methods |
AU2017207016B2 (en) | 2016-01-15 | 2021-09-16 | Curonix Llc | An implantable relay module |
US10244956B2 (en) | 2016-02-12 | 2019-04-02 | Nuvectra Corporation | Stimulation needle apparatus and method |
US10236709B2 (en) | 2016-05-05 | 2019-03-19 | Greatbatch Ltd. | Apparatus, system, and method for wireless charging of a device within a sterilizable vessel |
US10109844B2 (en) | 2016-11-02 | 2018-10-23 | Greatbatch Ltd. | Dual weld plug for an electrochemical cell |
US10493287B2 (en) | 2017-02-27 | 2019-12-03 | Medtronic, Inc. | Facilitating trusted pairing of an implantable device and an external device |
-
2016
- 2016-01-11 EP EP16735557.7A patent/EP3242712B1/en active Active
- 2016-01-11 JP JP2017536020A patent/JP6805153B2/en active Active
- 2016-01-11 AU AU2016205047A patent/AU2016205047B2/en active Active
- 2016-01-11 CN CN201680015091.3A patent/CN107427675B/en active Active
- 2016-01-11 ES ES16735557T patent/ES2725489T3/en active Active
- 2016-01-11 WO PCT/US2016/012918 patent/WO2016112398A1/en active Application Filing
- 2016-01-11 CA CA2973190A patent/CA2973190A1/en active Pending
- 2016-01-11 US US14/992,777 patent/US9895546B2/en active Active
-
2018
- 2018-01-03 US US15/861,580 patent/US10105542B2/en active Active
- 2018-05-02 US US15/969,706 patent/US10384067B2/en active Active
-
2019
- 2019-06-28 US US16/457,411 patent/US11123569B2/en active Active
-
2021
- 2021-08-20 US US17/407,768 patent/US20210379391A1/en not_active Abandoned
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1470432A (en) * | 1973-04-16 | 1977-04-14 | Vitatron Medical Bv | Apparatus for use in stimulating responses in a physiological system |
US20020068960A1 (en) * | 1999-03-24 | 2002-06-06 | Saberski Lloyd R. | Apparatus and methods for reducing pain and/or retraining muscles |
US20110144468A1 (en) * | 2004-06-10 | 2011-06-16 | Medtronic Urinary Solutions, Inc. | Systems and methods of neuromodulation stimulation for the restoration of sexual function |
US20070055318A1 (en) * | 2005-09-08 | 2007-03-08 | Medtronic, Inc. | External presentation of electrical stimulation parameters |
US20070270921A1 (en) * | 2006-05-17 | 2007-11-22 | Ndi Medical, Inc. | Systems and methods for patient control of stimulation systems |
US20100114259A1 (en) * | 2006-05-18 | 2010-05-06 | Uroplasty, Inc. | Method and Apparatus for Stimulating a Nerve of a Patient |
US20100222847A1 (en) * | 2007-10-24 | 2010-09-02 | Medtronic, Inc. | Transmission of power source usage information over a network |
US20090234302A1 (en) * | 2008-03-13 | 2009-09-17 | Medtronic,Inc. | Medical device and medical instrument alignment |
WO2009137683A2 (en) * | 2008-05-07 | 2009-11-12 | Hoffman Ross G | Transcranial direct current stimulation apparatus and methods |
WO2010111321A2 (en) * | 2009-03-27 | 2010-09-30 | Medtronic, Inc. | Conditional electrical stimulation in response to physiological information for pelvic health |
US20100318159A1 (en) * | 2009-06-12 | 2010-12-16 | Boston Scientific Neuromodulation Corporation | Miniature remote controller for implantable medical device |
US20120197338A1 (en) * | 2011-01-28 | 2012-08-02 | Medtronic, Inc. | Stimulation therapy including substantially simultaneous bilateral stimulation |
US20120215285A1 (en) * | 2011-02-21 | 2012-08-23 | Boston Scientific Neuromodulation Corporation | System for Communication with Implantable Medical Devices Using a Bridge Device |
US20130184773A1 (en) * | 2012-01-17 | 2013-07-18 | Imad Libbus | Vagus Nerve Neurostimulator With Multiple Patient-Selectable Modes For Treating Chronic Cardiac Dysfunction |
US20130261692A1 (en) * | 2012-03-27 | 2013-10-03 | Urologix Inc. | Neuromodulation system and related methods |
Non-Patent Citations (1)
Title |
---|
See also references of EP3242712A4 * |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11957910B2 (en) | 2011-01-03 | 2024-04-16 | California Institute Of Technology | High density epidural stimulation for facilitation of locomotion, posture, voluntary movement, and recovery of autonomic, sexual, vasomotor, and cognitive function after neurological injury |
US9662507B2 (en) | 2013-09-16 | 2017-05-30 | The Board Of Trustees Of The Leland Stanford Junior University | Multi-element coupler for generation of electromagnetic energy |
US9610457B2 (en) | 2013-09-16 | 2017-04-04 | The Board Of Trustees Of The Leland Stanford Junior University | Multi-element coupler for generation of electromagnetic energy |
US9687664B2 (en) | 2013-09-16 | 2017-06-27 | The Board Of Trustees Of The Leland Stanford Junior University | Multi-element coupler for generation of electromagnetic energy |
US9744369B2 (en) | 2013-09-16 | 2017-08-29 | The Board Of Trustees Of The Leland Stanford Junior University | Multi-element coupler for generation of electromagnetic energy |
US10039924B2 (en) | 2013-09-16 | 2018-08-07 | The Board Of Trustees Of The Leland Stanford Junior University | Wireless midfield systems and methods |
US9564777B2 (en) | 2014-05-18 | 2017-02-07 | NeuSpera Medical Inc. | Wireless energy transfer system for an implantable medical device using a midfield coupler |
US9583980B2 (en) | 2014-05-18 | 2017-02-28 | NeuSpera Medical Inc. | Midfield coupler |
US10105542B2 (en) | 2015-01-09 | 2018-10-23 | Axonics Modulation Technologies, Inc. | Patient remote and associated methods of use with a nerve stimulation system |
US10384067B2 (en) | 2015-01-09 | 2019-08-20 | Axonics Modulation Technologies, Inc. | Patient remote and associated methods of use with a nerve stimulation system |
US11123569B2 (en) | 2015-01-09 | 2021-09-21 | Axonics, Inc. | Patient remote and associated methods of use with a nerve stimulation system |
US11338148B2 (en) | 2015-05-15 | 2022-05-24 | NeuSpera Medical Inc. | External power devices and systems |
US11691015B2 (en) | 2017-06-30 | 2023-07-04 | Onward Medical N.V. | System for neuromodulation |
US11247044B2 (en) | 2017-10-25 | 2022-02-15 | Epineuron Technologies Inc. | Devices for delivering neuroregenerative therapy |
US11247045B2 (en) | 2017-10-25 | 2022-02-15 | Epineuron Technologies Inc. | Systems and methods for delivering neuroregenerative therapy |
US10589089B2 (en) | 2017-10-25 | 2020-03-17 | Epineuron Technologies Inc. | Systems and methods for delivering neuroregenerative therapy |
US11717689B2 (en) | 2018-04-19 | 2023-08-08 | Iota Biosciences, Inc. | Implants using ultrasonic communication for neural sensing and stimulation |
US11890474B2 (en) | 2018-04-19 | 2024-02-06 | Iota Biosciences, Inc. | Implants using ultrasonic communication for modulating splenic nerve activity |
US11969596B2 (en) | 2018-08-29 | 2024-04-30 | Iota Biosciences, Inc. | Implantable closed-loop neuromodulation device, systems, and methods of use |
US11672983B2 (en) | 2018-11-13 | 2023-06-13 | Onward Medical N.V. | Sensor in clothing of limbs or footwear |
US11672982B2 (en) | 2018-11-13 | 2023-06-13 | Onward Medical N.V. | Control system for movement reconstruction and/or restoration for a patient |
US11752342B2 (en) | 2019-02-12 | 2023-09-12 | Onward Medical N.V. | System for neuromodulation |
US11848090B2 (en) | 2019-05-24 | 2023-12-19 | Axonics, Inc. | Trainer for a neurostimulator programmer and associated methods of use with a neurostimulation system |
US11364381B2 (en) | 2019-10-01 | 2022-06-21 | Epineuron Technologies Inc. | Methods for delivering neuroregenerative therapy and reducing post-operative and chronic pain |
US11247043B2 (en) | 2019-10-01 | 2022-02-15 | Epineuron Technologies Inc. | Electrode interface devices for delivery of neuroregenerative therapy |
US11839766B2 (en) | 2019-11-27 | 2023-12-12 | Onward Medical N.V. | Neuromodulation system |
EP3900778A1 (en) * | 2020-04-23 | 2021-10-27 | ONWARD Medical B.V. | A neuromodulation system for planning and/or adjusting and/or providing a neuromodulation therapy |
EP3906965A1 (en) * | 2020-04-23 | 2021-11-10 | ONWARD Medical B.V. | A neuromodulation system for planning and/or adjusting and/or providing a neuromodulation therapy |
WO2022187471A1 (en) * | 2021-03-04 | 2022-09-09 | Inspire Medical Systems, Inc. | Assemblies and methods for wirelessly interfacing with an implantable medical device |
WO2022261001A1 (en) * | 2021-06-07 | 2022-12-15 | Boston Scientific Neuromodulation Corporation | Stimulation systems with user-specified routines and methods of making and using |
WO2023115132A1 (en) * | 2021-12-23 | 2023-06-29 | Saluda Medical Pty Ltd | Assisted programming system for neural stimulation therapy |
Also Published As
Publication number | Publication date |
---|---|
US11123569B2 (en) | 2021-09-21 |
AU2016205047B2 (en) | 2020-07-02 |
US10384067B2 (en) | 2019-08-20 |
US20210379391A1 (en) | 2021-12-09 |
US10105542B2 (en) | 2018-10-23 |
US20160199659A1 (en) | 2016-07-14 |
ES2725489T3 (en) | 2019-09-24 |
US20190321645A1 (en) | 2019-10-24 |
EP3242712A1 (en) | 2017-11-15 |
CN107427675A (en) | 2017-12-01 |
US20180133491A1 (en) | 2018-05-17 |
CA2973190A1 (en) | 2016-07-14 |
CN107427675B (en) | 2021-10-26 |
EP3242712A4 (en) | 2018-07-25 |
AU2016205047A1 (en) | 2017-07-20 |
US20180243572A1 (en) | 2018-08-30 |
US9895546B2 (en) | 2018-02-20 |
JP2018501024A (en) | 2018-01-18 |
EP3242712B1 (en) | 2019-04-10 |
JP6805153B2 (en) | 2020-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11123569B2 (en) | Patient remote and associated methods of use with a nerve stimulation system | |
US11484723B2 (en) | Attachment devices and associated methods of use with a nerve stimulation charging device | |
US9925381B2 (en) | Implantable nerve stimulator having internal electronics without ASIC and methods of use | |
US10682521B2 (en) | Attachment devices and associated methods of use with a nerve stimulation charging device | |
US11083903B2 (en) | Methods and systems for frequency adjustment to optimize charging of implantable neurostimulator |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16735557 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2973190 Country of ref document: CA Ref document number: 2017536020 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2016735557 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2016205047 Country of ref document: AU Date of ref document: 20160111 Kind code of ref document: A |